Introduction {#s1}
============

The endolysosomal membrane system comprises a dynamic network of interconnected compartments that mediates sorting or degradation of endocytosed proteins ([@bib32]; [@bib67]). Many factors that regulate endolysosomal trafficking are implicated in human disease, including neurodegenerative disorders ([@bib75]; [@bib76]). Among these, retromer is a complex that recycles selected protein cargoes from the endosome to the *trans*-Golgi network or the plasma membrane ([@bib4]; [@bib45]). Mutations in *VPS35*---encoding a retromer core protein---are a rare cause of familial Parkinson's disease ([@bib92]; [@bib103]), and retromer has also been linked to endocytic trafficking and processing of the Amyloid Precursor Protein and Tau in Alzheimer's disease ([@bib58]; [@bib87]; [@bib97]). Despite its emerging importance in neurodegenerative disease, the requirements of retromer in neurons and particularly within the aging nervous system remain incompletely understood.

Originally discovered in the yeast *Saccharomyces cerevisiae* ([@bib73]), the heterotrimeric core proteins of the retromer, VPS35, VPS26, and VPS29, are highly conserved among eukaryotes ([@bib35]). Retromer components are broadly expressed, including in the invertebrate nervous system ([@bib26]; [@bib94]) and throughout the mammalian brain ([@bib1]; [@bib85]). In murine neurons, retromer is present in both axons and dendrites, and at the synapse ([@bib59]; [@bib85]). Post-synaptically, retromer appears important for trafficking of AMPA, β2 adrenergic, and perhaps other neurotransmitter receptors to the dendritic membrane ([@bib9]; [@bib59]; [@bib83]). In rat mesencephalic cultures, retromer also participates in pre-synaptic dopamine transporter trafficking ([@bib99]), and studies of *Vps35* at the *Drosophila* neuromuscular junction suggest a requirement for synaptic vesicle recycling ([@bib26]). *Vps35*-deficient mice exhibit both defective hippocampal neurotransmission ([@bib58]) and dopaminergic insufficiency ([@bib81]; [@bib82]), leading to impairments in memory and locomotion, respectively.

Retromer regulates lysosomal degradation pathways, including autophagy, which are important for quality control and brain homeostasis ([@bib49]; [@bib56]). In the absence of retromer, many protein cargoes are misdirected to the lysosome ([@bib4]; [@bib45]; [@bib96]), potentially overwhelming degradative capacity, leading to lysosomal expansion and cellular stress. For example, in the *Drosophila* retina, loss-of-function for *Vps35* or *Vps26* results in accumulation of the visual pigment, Rhodopsin-1 (Rh1), within photoreceptors, ultimately causing neuronal dysfunction and loss ([@bib94]). Nevertheless, most investigations of the retromer in lysosomal function have relied on cell culture paradigms using non-neuronal cell types ([@bib11]; [@bib28]; [@bib102]). Ablation of *VPS35* in the mouse germline is embryonic lethal ([@bib97]), and both *Vps35* and *Vps26* similarly have essential developmental requirements in *Drosophila* ([@bib14]; [@bib17]; [@bib65]; [@bib77]; [@bib79]; [@bib96]).

Notably, among the retromer core proteins, the precise roles of each subunit remain incompletely defined, with especially scant data on VPS29. VPS29 binds the VPS35 C-terminus ([@bib10]; [@bib24]; [@bib36]). Deletion of *Vps29* in yeast or *Caenorhabditis elegans* phenocopies *Vps35* loss-of-function ([@bib43]; [@bib72]). In mammalian epithelial cell culture, reducing VPS29 results in apparent destabilization and degradation of both VPS35 and VPS26 ([@bib18]; [@bib28]). Reciprocally, pharmacological chaperones targeting the VPS35-VPS29 interface can stabilize the complex and enhance retromer function ([@bib54]; [@bib100]; [@bib39]). Here, we have generated and characterized a *Drosophila Vps29* null allele with a focus on in vivo requirements in the nervous system. We identify an unexpected requirement for Vps29 in the regulation of retromer localization, and further highlight a role in synaptic vesicle recycling and lysosomal function in the aging brain.

Results {#s2}
=======

*Vps29* is required for age-dependent retinal function {#s2-1}
------------------------------------------------------

*Drosophila Vps29* is predicted to encode a 182 amino-acid protein that is 93% similar (83% identical) to human VPS29. Prior studies of *Vps29* in flies have relied on RNA-interference knockdown approaches ([@bib40]). We instead generated a *Vps29* null allele using a CRISPR-Cas9 strategy ([@bib38]). In the resulting mutant, *Vps29^1^*, the entire coding sequence was replaced by the visible marker gene, *y^wing2+^* ([Figure 1A](#fig1){ref-type="fig"}). Unexpectedly, *Vps29^1^* was homozygous viable, whereas both *Vps35* and *Vps26* mutants are lethal ([@bib17]; [@bib94]). Loss of the *Vps29* genomic sequence in null animals was confirmed by PCR ([Figure 1B](#fig1){ref-type="fig"}) and sequencing of the insertional breakpoints, and we were not able to detect any protein using an anti-Vps29 antibody on western blots from fly head homogenates ([Figure 1C](#fig1){ref-type="fig"}). Although viable, *Vps29^1^* homozygotes are recovered at ratios below Mendelian expectation ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We also recovered viable *Vps29^1^* animals lacking both maternal and zygotic protein when crossing homozygous females to heterozygous males. Notably, *Vps29^1^* mutant flies exhibit a modestly reduced survival (\~50--60 days versus \~75 days for controls), and this result was confirmed when *Vps29^1^* animals were crossed to the deficiency, *Df(2L)Exel6004* ([Figure 1D](#fig1){ref-type="fig"}). The reduced survival seen in *Vps29* null animals was also rescued by a 23 kb P\[acman\] bacterial artificial chromosome ([@bib89]) containing the *Vps29* genomic locus, establishing specificity.

![*Vps29* is required for age-dependent retinal function.\
(**A**) The *Vps29* genomic locus is shown, highlighting reagents used in this study. In the null allele, *Vps29^1^*, the gene coding sequence (blue, 2L: 1150852--1151420) is replaced by a *ywing^2+^* marker gene. *Vps29^WT.GFP^* and *Vps29^L152E.GFP^* are identical N-terminal tagged-Vps29 alleles, except for the L152E variant. A chromosomal deficiency *Df(2L)Exel6004* is shown, with the deleted regions indicated by dashed lines. A bacterial artificial chromosome (BAC) (yellow) was used for transgenic genomic rescue (*GR*). (**B**) Genomic polymerase chain reaction (PCR) showing loss of Vps29 coding sequence in *Vps29^1^* homozygotes versus control (w) flies. P1, P2, and P3 denote expected PCR products from primer pairs targeting *Vps29* genomic sequence. As an additional control, PCR was also performed for *Vps35* genomic sequence. We also performed PCRs using primer pairs that span both sides of the breakpoint junctions abutting the inserted *ywing^2+^* marker gene cassette (not shown), and these products were Sanger sequenced to confirm the depicted molecular lesion. (**C**) Western blot from adult heads probed with anti-Vps29 antibody, confirming *Vps29^1^* is a protein null allele. (**D**) *Vps29^1^* homozygotes and *Vps29^1^/Df* transheterozygotes (*Vps29^1^/Df(2L)Exel6004*) show reduced survival that is rescued by the *Vps29* genomic rescue strain (*Vps29^1^/Df; GR/+*). Quantitation based on n = 200--235 per group. See also [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. (**E**) Representative ERG traces at 1- and 10 days after generation of *ey-FLP* clones from (i) control (*FRT40A*), (ii) *Vps29^1^*, or (iii) *Vps35^MH20^*. Flies were raised using an alternating 12 hr light/dark cycle (12h-LD) or in complete darkness. Loss of either *Vps29* or *Vps35* disrupted light-induced depolarization (arrow) in 10-day-old flies. On- and off- transient ERG potentials (top and bottom arrowheads, respectively) were also lost. Raising flies in the dark restored ERG depolarization, but not the transients, indicating persistent defects in synaptic transmission. (**F--G**) Quantification (n = 6--8) of ERG depolarization and on-transient potentials. 'X' denotes undetectable on-transients in 20-day-old animals. See also [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}. (**H**) Compared with controls (*FRT40A* clones), ERG transient potentials are extinguished by rapid stimulation in *Vps29^1^* clones. Consistent results were obtained using either *ey-FLP* or *ey^3.5^-FLP*, which targets presynaptic neurons only. Flies were raised in complete darkness and examined at 1 day. See also [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}. (**I**) Rescue of *Vps29^1^* synaptic transmission defects by pan-neuronal expression (*nSyb-GAL4* driver) of either *Drosophila Vps29* or *Vps35* (*dVps29* and *dVps35*) or human *Vps29* (*hVps29-1,−2,* or *−3*, representing three alternate isoforms). Quantification of ERG on-transients in 15-day-old flies (n = 9--12 per group) from the following genotypes: (1) *Vps29^1^;nSyb-Gal4/+*; (2) *Vps29^1^;nSyb-Gal4/UAS-dVps29*; (3-5) *Vps29^1^;nSyb-Gal4/UAS-hVps29*; and (6) *Vps29^1^;nSyb-Gal4/UAS-dVps35*. Statistical analysis was based on log-rank test with Bonferroni\'s correction (**D**) or one-way ANOVA (**F, G, I**). All error bars denote SEM. n.s., not significant; \*\*, p\<0.01; \*\*\*, p\<0.001.](elife-51977-fig1){#fig1}

As introduced above, the retromer plays an essential role in the endocytic recycling of Rh1 in the *Drosophila* eye, thereby enabling proper phototransduction ([@bib94]). Consequently, loss of either *Vps35* or *Vps26* leads to aberrant Rh1 trafficking, resulting in lysosomal stress and progressive retinal degeneration. In order to determine if *Vps29* is similarly required, we generated somatic clones of either *Vps29^1^* or the *Vps35^MH20^* null allele in the fly eye using the *eyeless* (*ey*)-FLP/FRT system ([@bib61]), and monitored degeneration using electroretinograms (ERGs). Compared with control clones (*FRT40A*), removing either retromer component from photoreceptors disrupted light-induced depolarization in 10-day-old animals; however, the *Vps29* phenotype was less severe than that due to loss of *Vps35* ([Figure 1E,F](#fig1){ref-type="fig"}). Consistent with other retromer components, the *Vps29^1^* retinal degeneration phenotype was suppressed when flies were raised in the dark, which eliminates phototransduction and the concomitant endocytosis of Rh1. Age- and light-dependent retinal degeneration in the absence of *Vps29* was further confirmed by histology ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), and this phenotype was also reversed by introduction of the *Vps29* genomic rescue construct. On further inspection of the ERG traces, we noticed that both *Vps29^1^* and *Vps35^MH20^* appear to disrupt synaptic transmission ([Figure 1E,G](#fig1){ref-type="fig"}), based on progressive reduction in the on- and off-transient potentials in aging animals ([@bib2]). Interestingly, however, whereas raising animals in the dark rescued phototransduction, the ERG transient potential phenotypes persisted, suggesting a role for retromer at the synapse that is independent of Rh1 recycling.

In our ERG experiments, we also noticed that whereas the transient potentials are preserved in newly eclosed animals with *Vps29* or *Vps35* mutant eye clones, they were poorly sustained throughout the recordings. We therefore repeated our ERG experiments in retinae with either *Vps29^1^* or *Vps35^MH20^* mutant clones, but instead using a rapid light stimulation paradigm. Indeed, we documented a progressive decline in the on- and off-transient potentials following rapid stimulation, and consistent results were also obtained using the *ey^3.5^-FLP* driver ([@bib55]), which selectively targets presynaptic neurons ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). This 'run-down' phenotype is characteristic of mutants that disrupt synaptic vesicle recycling ([@bib22]), suggesting that retromer is required for this process. We further demonstrated that the retinal synaptic transmission phenotype in *Vps29^1^* homozygotes was fully rescued using the pan-neuronal expression driver (*nSyb-GAL4*) and a full-length *Drosophila Vps29* cDNA (*nSyb\>Vps29*) ([Figure 1I](#fig1){ref-type="fig"}). Finally, similar rescue was observed when expressing three alternate human *Vps29* isoforms, consistent with functional conservation. Surprisingly, we also found that pan-neuronal overexpression of *Vps35* (*nSyb\>Vps35*) partially restored synaptic transmission in *Vps29^1^* homozygous animals. In combination with the somewhat weaker phenotype, this result suggests that Vps29 may function primarily to potentiate the activity of other retromer subunits in the retina, such that Vps35 overexpression is compensatory. In sum, whereas Vps29 appears dispensable for retromer function during embryogenesis and development, these studies reveal a requirement in the aging nervous system for phototransduction and synaptic transmission.

Retromer regulates synaptic vesicle endocytosis and recycling {#s2-2}
-------------------------------------------------------------

To further explore the requirement of retromer at synapses, we next turned to the larval neuromuscular junction (NMJ). Based on previous work, Vps35 is present at both the NMJ pre- and post-synapse, and loss of *Vps35* causes synaptic terminal overgrowth and altered neurophysiology suggestive of synaptic vesicle recycling defects ([@bib26]; [@bib34]; [@bib47]; [@bib93]). We therefore examined whether *Vps29* mutants show similar phenotypes. Indeed, NMJ preparations from *Vps29^1^* homozygous larvae revealed a modest but significant increase in synaptic bouton numbers, consistent with synaptic overgrowth ([Figure 2A](#fig2){ref-type="fig"}). However, both amplitude and frequency of NMJ miniature excitatory junction potentials (mEJPs) were unaffected following loss of *Vps29* ([Figure 2B](#fig2){ref-type="fig"}). Similarly, excitatory junction potentials (EJPs) were also preserved ([Figure 2C](#fig2){ref-type="fig"}). These results suggest that *Vps29* is neither required for spontaneous nor evoked synaptic vesicle release. However, high-frequency stimulation (10 Hz for 10 min) provoked a marked synaptic depression at the *Vps29^1^* NMJ ([Figure 2D](#fig2){ref-type="fig"}). These data provide further support for the role of Vps29 in synaptic vesicle recycling.

![Retromer regulates synaptic vesicle endocytosis and recycling.\
(**A**) *Vps29* loss of function causes an increased number of synaptic terminal boutons at the larval neuromuscular junction (NMJ). NMJ preparations from *Vps29^1^* homozygotes or control larvae (*GR* = *Vps29^1^;GR/+*) were stained with an antibody against horseradish peroxidase, and Type IIb boutons at abdominal segments A2 and A3 were quantified (n = 5 animals per group). The *Vps29* transgenic BAC (GR) was heterozygous for all comparisons. (**B**) Larval NMJ electrophysiology in *Vps29^1^* reveals normal miniature excitatory junction potential (mEJP) amplitude and frequency (in 2 min) (n = 14--16). (**C**) Evoked excitatory junction potentials (EJPs) are normal in the absence of *Vps29*. Representative EJP traces from *Vps29^1^* and *Vps29^1^;GR/+* (control, *GR*) larvae and quantification (n = 13--15). 0.2 Hz stimulation was performed using 0.5 mM Ca^2+^. (**D**) *Vps29^1^* NMJs show synaptic depression following rapid stimulation (10 Hz, 0.5 mM extracellular Ca^2+^). Representative traces (10 min) are shown, with quantification (n = 13). Data was normalized to initial EJP amplitude. (**E**) *Vps29^1^* NMJs show reduced FM 1-43 dye uptake following KCl stimulation, consistent with impaired synaptic vesicle endocytosis. FM1-43 signal intensity (per bouton area) was quantified (n = 8--11). See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Statistical analysis (**A--E**) based on Student's t-test. All error bars denote SEM. n.s., not significant; \*, p\<0.05; \*\*\*, p\<0.001.](elife-51977-fig2){#fig2}

The NMJ synaptic run-down phenotype is characteristic of mutants causing defective endocytosis ([@bib3]; [@bib90]; [@bib98]). To further investigate if synaptic vesicle endocytosis requires the retromer, we performed dye uptake studies in animals lacking *Vps29* or *Vps35* ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Larval preparations were stimulated with potassium chloride in the presence of extracellular buffer containing the fluorescent dye FM 1--43, permitting quantification of endocytic flux ([@bib91]). In control animals, FM 1--43 dye was rapidly internalized at the presynaptic membrane. However, NMJs from either *Vps29^1^* or *Vps35^MH20^* homozygous animals significantly reduced FM dye uptake. These results are consistent with models whereby retromer either directly or indirectly supports vesicle recycling at the presynapse.

*Vps29* regulates retromer localization and is required in the aging nervous system {#s2-3}
-----------------------------------------------------------------------------------

The requirement of retromer during *Drosophila* embryogenesis has hindered systematic characterization of its function in the adult nervous system, with the exception of studies in the retina relying on clonal analysis of *Vps35* and *Vps26* ([@bib94]). Although *Vps29* is dispensable for embryonic development, our results (above) establish a largely conserved Vps29 requirement for retromer function in the retina and at the NMJ synapse. We therefore studied *Vps29* null adult animals to further explore retromer requirements in the adult brain. Except for the aforementioned retinal requirement, we did not observe obvious morphological defects or apparent evidence of neurodegeneration in the brains of 45-day-old *Vps29^1^/Df* adults based on hematoxylin and eosin staining of paraffin sections ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In order to examine nervous system function, we next tested the startle-induced negative geotactic response (climbing) ([@bib13]; [@bib69]). Although locomotor behavior was normal in newly eclosed *Vps29* null adults, climbing ability significantly declined with aging ([Figure 3A](#fig3){ref-type="fig"}). Our results are consistent with published work using RNA-interference to target *Vps29* ([@bib40]). *Vps29^1^* homozygous flies manifested a stronger locomotor dysfunction phenotype than *Vps29^1^/Df*, suggesting the presence of a potential modifier; however, both genotypes were fully rescued by the genomic BAC transgene. Similar results were obtained for the *Vps29* retinal degeneration phenotype ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Locomotor defects in *Vps29^1^* homozygous animals were also partially rescued by pan-neuronal *Vps29* expression (*nsyb\>Vps29*), and human *VPS29* showed comparable rescue activity ([Figure 3B](#fig3){ref-type="fig"}). Overall, these results suggest *Vps29* is required for the maintenance of nervous system function in aging animals.

![Progressive locomotor impairment in *Vps29* mutants but preserved Vps35 and Vps26 protein levels.\
(**A**) *Vps29^1^/Df* and *Vps29^1^* adults demonstrate age-dependent locomotor impairment, based on startle-induced negative geotaxis, and this phenotype is fully rescued by a single, heterozygous copy of the *Vps29* BAC transgenic (*Vps29^1^/Df; GR/+* and *Vps29^1^; GR/+*). Control: *yw/w*. The *Vps29^1^* homozygote genotype manifests a stronger locomotor phenotype than *Vps29^1^/Df* (p\<0.01 in comparisons at 20 days). Quantification based on n = 4 groups, each consisting 14--16 flies. See also [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}. (**B**) Pan-neuronal expression of either *Drosophila* or human *Vps29* (dVps29 or hVps29, respectively), using the *nsyb-GAL4* driver rescues the *Vps29^1^* locomotor phenotype. Quantification based on n = 4 groups of 20-day-old flies from the following genotypes: (1) *Vps29^1^;nSyb-Gal4/+*; (2) *Vps29^1^;nSyb-Gal4/UAS-dVps29*; and (3-5) *Vps29^1^;nSyb-Gal4/UAS-hVps29*. (**C**) Vps35 and Vps26 protein levels are normal in the absence of *Vps29*. Western blots of adult fly head homogenates from either *Vps29^1^, Vps35^GFP^* homozygotes or controls (*Vps35^GFP^*), probed for Vps35^GFP^ (anti-GFP), Vps26, or Tubulin (loading control). Quantification based on n = 3 replicate experiments. See also [Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}. (**D**) The association of Vps35 and Vps26 proteins is preserved in the absence of *Vps29*. Vps35^GFP^ was immunoprecipitated from either *Vps29^1^, Vps35^GFP^* homozygotes or control animals (*Vps35^GFP^*) (2 day old), and western blots were probed for Vps35^GFP^ (anti-GFP), Vps26, and Vps29. Quantification based on n = 4 replicate experiments. Statistical analysis based on one-way ANOVA (**A--C**) or Student's t- test (**D**). All error bars denote SEM. n.s., not significant; \*\*, p\<0.01; \*\*\*, p\<0.001.](elife-51977-fig3){#fig3}

In prior studies of HeLa cell cultures, *VPS29* knockdown caused reduced levels of both VPS35 and VPS26, likely due to destabilization of the retromer trimer complex and subunit turnover ([@bib18]; [@bib28]). Reciprocally, enhancing interactions between VPS29 and VPS35 promotes retromer stability ([@bib54]; [@bib100]). However, Vps35 and Vps26 protein levels were unaffected in *Vps29* null animals (either *Vps29^1^* homozygotes or *Vps29^1^/Df*), based on western blots from either whole larvae or adult *Drosophila* heads ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}), including from 30-day-old animals. Furthermore, we confirmed that Vps35 and Vps26 remain tightly associated in the absence of Vps29, based on coimmunoprecipitation assays ([Figure 3D](#fig3){ref-type="fig"}). Thus, Vps35-Vps26 complex assembly and stability in the nervous system are preserved in *Drosophila* lacking *Vps29*.

Besides expression and stability, retromer function is tightly regulated by its subcellular localization ([@bib16]; [@bib44]). We examined retromer expression and localization in the adult fly brain using endogenously tagged fluorescent protein alleles, encoding either Vps35^RFP^ or Vps35^GFP^ ([@bib33]), as well as Vps29^GFP^ ([Figure 1A](#fig1){ref-type="fig"}) fusion proteins. As expected, Vps29 and Vps35 appeared to colocalize, and were broadly expressed in the *Drosophila* brain, including the antennal lobes and the mushroom body (α-/β- lobes and peduncles) ([Figure 4A,B](#fig4){ref-type="fig"}). We confirmed that most of the observed staining in the adult brain, including within neuropil regions, derived from neuronal Vps35, as this signal was lost following neuronal-specific knockdown ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). However, in *Vps29^1^* homozygous animals, Vps35 showed a striking redistribution, shifting from neuropil to enrichment in soma, and forming large perinuclear puncta ([Figure 4C](#fig4){ref-type="fig"}). Moreover, Vps35 was mislocalized in brains from 1-day-old adults and this result did not significantly change with aging. Consistent results were obtained in the lamina, where retinal photoreceptors synapse on second-order neurons in the visual pathway ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Specifically, in *Vps29^1^* homozygotes, both Vps35 and Vps26 accumulated in the lamina cortex and staining was attenuated in the lamina neuropil. Lastly, we also found that Vps35 was depleted from the *Vps29^1^* homozygous larval brain neuropil and at the NMJ synaptic bouton; however, we did not detect any apparent enrichment in motor neuron cell bodies ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Overall, these data suggest that Vps29 is required for normal retromer localization within neurons.

![*Vps29* regulates Vps35 localization in the adult brain.\
(**A**) Vps29^GFP^ (anti-GFP, green) and Vps35^RFP^ (red) are expressed throughout the adult brain and co-localize. Boxed region of interest including antennal lobe (top row) is shown magnified (bottom row). Representative puncta (arrowhead) co-staining for Vps35 and Vps29 is further magnified in inset. Scale bars, 100 µm. (**B**) Vps35^GFP^ (anti-GFP, green) is modestly enriched in neuropil regions, including the antennal lobes and the mushroom body (α-/β- lobes and peduncles). Scale bars, 100 µm. See also [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}. (**C**) In the absence of *Vps29*, Vps35^GFP^ (green) protein is redistributed in the adult brain, shifting from neuropil to soma and forming large perinuclear puncta. Neuronal nuclei are labeled with anti-Elav (red). Within the boxed region of interest, including antennal lobe and surrounding nuclei, the GFP intensity ratio (perinuclear to neuropil) was quantified (n = 3) in *Vps29^1^, Vps35^GFP^* homozygotes or *Vps35^GFP^* controls. Scale bars, 100 µm. See also [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. (**D**) Schematic highlighting the Rab7 cycle including GTP-bound (active) and GDP-bound (inactive) forms and putative interactions regulating retromer recruitment and release. (**E**) In *Vps29* mutants, Vps35^GFP^ (green) colocalizes with Rab7 (anti-Rab7, red), which appears increased and similarly redistributed from neuropil to soma. The region of interest centered on the antenna lobe is indicated in the boxed region of the lower power image (maximal intensity projection); the magnified images are representative anterior single sections taken through the antennal lobe. Scale bars, 100 µm. See also [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}. (**F**) Rab7 protein levels are increased in the absence of *Vps29*. Western blots of adult head homogenates, including *Vps29^1^, Rab7^EYFP^* homozygotes or *Rab7^EYFP^* controls (2-day-old), were probed for Rab7-YFP (anti-GFP) and Tubulin (loading control). Quantification based on n = 4 replicate experiments. See also [Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}. (**G**) Rab7 protein levels are increased in the constitutive active, 'GTP-locked' *Rab7^Q67L^* mutant. Western blots of adult head homogenates from 5-day-old animals were probed for Rab7 or Actin, including the following genotypes: (1, *Rab7-Gal4 \> Rab7* CA) *UAS-Venus-Rab7 ^Q67L^/+; Rab7-Gal4/+*; (2, *Rab7-Gal4 \> Rab7* WT) *UAS-Venus-Rab7 ^WT^/+; Rab7-Gal4/+*; (3, *Rab7-Gal4 \> Rab7* DN) *UAS-Venus-Rab7 ^T22N^/+; Rab7-Gal4/+*; (4, control) *w*. Venus-tagged or endogenous Rab7 protein levels were separately quantified, based on n = 4 replicate experiments. See also [Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}. Statistical analysis was based on Student's t-test (**C, F**) or one-way ANOVA (**G**). To address the possibility of a modestly skewed distribution, the data in **C** were log~2~-transformed, and the results of t-tests were unchanged. All error bars denote SEM. \*, p\<0.05; \*\*, p\<0.01.](elife-51977-fig4){#fig4}

*Vps29* interacts with *Rab7* and *TBC1D5* {#s2-4}
------------------------------------------

Based on cell culture studies, Vps35 is recruited to endosomal membranes by the Rab7 GTPase ([@bib74]), and *VPS29* knockdown has been previously suggested to increase GTP-bound, activated Rab7 ([@bib28]). We therefore examined whether dysregulation of Rab7 may similarly participate in neuronal retromer localization in vivo ([Figure 4E--G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Indeed, in the adult brain of *Vps29^1^* homozygotes, the Rab7 signal appeared strongly increased and was restricted to a somatic, perinuclear pattern with relative depletion from neuropil. The Arl8 GTPase, which functions coordinately with Rab7 in endolyososmal maturation ([@bib30]; [@bib51]), was increased in a similar pattern in the *Vps29^1^* adult brain. Based on prior studies ([@bib46]; [@bib68]), Arl8 localizes to the lysosomal membrane, and we confirmed this using an independent lysosomal marker, Spinster-GFP ([@bib80]). Importantly, mislocalized Vps35 strongly costained with perinuclear Rab7 and Arl8, suggesting enrichment at the late endosome and/or lysosome. On western blots, we documented an increase in Rab7 protein in either *Vps29^1^* homozygotes or *Vps29^1^/Df* ([Figure 4F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}). To examine if the change in Rab7 expression level reflects an altered ratio of GTP-bound (active) to GDP-bound (inactive) Rab7 protein ([Figure 4D](#fig4){ref-type="fig"}), we leveraged available fly strains harboring Venus-tagged *Rab7* transgenes ([@bib7]), including wildtype *Rab7*, the 'GTP-locked' mutant *Rab7^Q67L^* and the 'GDP-locked' mutant *Rab7^T22N^*, under the control of identical *Rab7* promoter elements (*Rab7-GAL4*). We found that the constitutively active, GTP-locked Rab7^Q67L^ protein was present at higher levels ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}). Moreover, endogenous wildtype Rab7 was also increased, potentially reflecting a compensatory cellular response. These data support a model in which loss of *Vps29* promotes Rab7 activation, redistribution of active Rab7 from axon to soma, and subsequent recruitment of Vps35.

If Rab7 activation mediates the disruption in retromer localization and function in *Vps29* mutants, our model predicts that reduction in Rab7 may rescue the neuronal requirements for Vps29. Indeed, although complete loss-of-function for *Rab7* is lethal, removing one copy (*Rab7^Gal4-KO^/+*) ([@bib7]) partially rescued the age-dependent locomotor impairment and synaptic transmission defects manifest in *Vps29^1^/Df* animals ([Figure 5A,B](#fig5){ref-type="fig"}). Reduction of *Rab7* also restored synaptic vesicle endocytosis at the larval NMJ in *Vps29^1^* homozygotes, based on the FM 1--43 dye uptake assay ([Figure 5C](#fig5){ref-type="fig"}). In mammalian cell culture studies, VPS29 regulates Rab7 activity via recruitment of the GTPase-activating protein (GAP), TBC1D5 ([@bib27]; [@bib74]). *Drosophila* has a single ortholog of TBC1D5 that is well-conserved (28% identity/47% similarity) ([@bib21]). Consistent with our model, pan-neuronal overexpression of *dTBC1D5* (*nsyb\>dTBC1D5*) normalized Rab7 protein levels ([Figure 5D](#fig5){ref-type="fig"}) and partially rescued the synaptic transmission defect in *Vps29* mutants ([Figure 5E](#fig5){ref-type="fig"}). Next, we introduced a point mutation at the *Vps29* genomic locus causing the single amino-acid substitution, *Vps29^L152E^* ([Figure 1A](#fig1){ref-type="fig"}); mutation of this conserved residue has been shown to disrupt the interaction with TBC1D5 in mammalian cells ([@bib27]; [@bib28]). *Vps29^L152E^* failed to complement *Vps29^1^* ([Figure 5F--H](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), causing age-dependent photoreceptor synaptic transmission defects and locomotor impairment. The residual, albeit weak on-transient ERG potential in *Vps29^1^/Vps29^L152E^* adults suggest that *Vps29^L152E^* is a hypomorphic allele. Moreover, Vps29^L152E^ was expressed at higher levels and Rab7 was also increased, as in *Vps29^1^*. Overall, these results indicate that Vps29 regulates retromer localization coordinately with Rab7 and TBC1D5.

![Reduction of Rab7 or overexpression of TBC1D5 suppresses *Vps29* mutant phenotypes.\
(**A--C**) Reduction of *Rab7* rescues *Vps29* mutant phenotypes, including progressive locomotor impairment (**A**), synaptic transmission (**B**), and synaptic vesicle endocytosis at the larval NMJ (**C**). (**A**) Quantification of locomotor behavior based on n = 4 groups, each consisting of 12--15 flies. (**B**) Quantification of electroretinogram (ERG) on-transients (n = 12--13) from adults raised using a 12 hr light/dark cycle. (**C**) FM 1-43 dye uptake signal intensity per NMJ bouton area was quantified (n = 7--9). (**D**) Pan-neuronal overexpression of *dTBC1D5* (*nsyb\>dTBC1D5*) restores Rab7 protein level in flies lacking *Vps29*. Western blots of adult fly head homogenates (30-day-old) were probed for Rab7 and Tubulin (loading control), and quantified based on n = 4 replicate experiments, including the following genotypes: (1, red) *Vps29^1^;nSyb-GAL4/+*; (2, grey) *Vps29^1^;nSyb-GAL4/UAS-dVps29*; (3, blue) *Vps29^1^;nSyb-GAL4/UAS-dTBC1D5*. (**E**) Pan-neuronal overexpression of *dTBC1D5* (*nsyb\>dTBC1D5*) rescues synaptic transmission in *Vps29^1^* mutants. Quantification of ERG on-transients (n = 8) from adults raised using a 12 hr light/dark cycle. (**F, G**) The *Vps29^L152E^* mutation, predicted to disrupt the Vps29-TBC1D5 interaction, fails to complement *Vps29^1^*, causing impaired synaptic transmission (**F**) and locomotor impairment (**G**). Quantification of ERG on-transients in 30-day-old flies raised in complete darkness (**F**) (n = 12--14) or locomotor behavior in 20-day-old flies (**G**) (n = 5--6 groups). See also [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. (**H**) The *Vps29^L152E^* mutation causes increased expression of Vps29 (anti-GFP, green) and Rab7 (anti-Rab7, red). Whole-mount brain immunofluorescence shown for *Vps29^L152E.GFP^* or *Vps29^WT.GFP^* homozygotes (2-day-old adults). Scale bars, 100 µm. See also [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}. Statistical analysis based on Student's t-test (**A, F, G**) or one-way ANOVA (**B--E**). All error bars denote SEM. n.s., not significant; \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001.](elife-51977-fig5){#fig5}

Loss of *Vps29* causes lysosomal dysfunction during aging {#s2-5}
---------------------------------------------------------

As introduced above, retromer mediates the recycling of protein cargoes from the endolysosomal system to the *trans*-Golgi network or plasma membrane. Moreover, retromer loss may impair lysosomal biogenesis and function, for example by disrupting delivery of key hydrolases ([@bib50]). In the *Drosophila* retina, besides aberrant trafficking of Rh1 ([@bib94]), loss of *Vps35* causes accumulation of ceramide lipid species ([@bib39]), which contributes to lysosomal expansion, cellular stress, and ultimately photoreceptor loss. We confirmed that glucosylceramide similarly accumulates in *Vps29^1^* homozygous photoreceptors ([Figure 6A](#fig6){ref-type="fig"}), consistent with the retinal degeneration phenotype. In order to better understand the proximal consequences of retromer mislocalization that lead to neuronal dysfunction, we performed a series of experiments to assay lysosomal function in the adult brains of *Vps29* mutants. We first examined the lysosomal proteases, cathepsin D (CTSD) and cathepsin L (CTSL). These enzymes are each synthesized as propeptides in the endoplasmic reticulum (ER) and become active following cleavage in the acidic, lysosomal milieu. Lysosomal dysfunction therefore commonly leads to reduced levels of mature cathepsins and increased levels of the immature proforms ([@bib23]; [@bib37]). We detected normal levels of mature CTSL and increased mature CTSD in adult head homogenates from 1-day-old *Vps29^1^/Df* animals ([Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). However, in 30-day-old animals, we found that the uncleaved proforms of both cathepsins were sharply increased, consistent with progressive lysosomal dysfunction with aging.

![Loss of *Vps29* causes age-dependent, progressive lysosomal dysfunction in the brain.\
(**A**) In the absence of *Vps29*, glucosylceramide (anti-GlcCer, green) accumulates in the retina. Tissue is counterstained for actin (phalloidin, red) to highlight the photoreceptor rhabdomeres. Glucosylceramide signal was quantified from a 36.94 × 36.94 µm^2^ region encompassing \~10 ommatidia in 30-day-old animals (n = 10) raised in dark conditions, including *GMR-w-RNAi/+; Vps29^1^; GR/+* (controls) and *GMR-w-RNAi/+; Vps29^1^*. Eye pigment was removed using RNAi against the *w* gene to reduce auto-fluorescence. A representative ommatidium (boxed) is shown at higher-power (right). Scale bars, 5 µm. (**B**) The uncleaved, CTSL proform is increased in aged animals lacking *Vps29*, consistent with diminished lysosomal proteolytic capacity. Western blots from adult fly head homogenates were probed for CTSL and Tubulin (loading control), and quantified based on n = 3 replicate experiments. See also [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}. (**C**) Autophagic flux is reduced in aged animals lacking *Vps29*, and this phenotype is suppressed by reduction of *Rab7*. Western blots of adult head homogenates were probed for autophagic markers, including p62, Atg8, polyubiquitin (FK1), or Tubulin (loading control), and quantified based on n = 8 replicate experiments. See also [Figure 6---figure supplement 1B,C](#fig6s1){ref-type="fig"}. Statistical analysis based on Student's t-test (**A, B**) and one-way ANOVA (**C**). All error bars denote SEM. n.s., not significant; \*, p\<0.05; \*\*, p\<0.01.](elife-51977-fig6){#fig6}

We next examined well-established markers of lysosomal autophagy, which plays a critical role in nervous system homeostasis and neurodegeneration ([@bib49]; [@bib56]). Substrate degradation is triggered when Atg8-decorated autophagosomes fuse with lysosomes, leading to turnover of Ref(2)P/p62 and concomitant clearance of polyubiquitinated proteins. We did not observe any accumulation of these markers in heads from either 1- or 30-day-old *Vps29^1^/Df* flies ([Figure 6---figure supplement 1B,C](#fig6s1){ref-type="fig"}), consistent with preserved autophagic flux. Interestingly, however, at more extreme ages (45 days), *Vps29* mutants showed evidence of accelerated autophagic failure, with more significant elevation of both p62 and Atg8, and accumulation of polyubiquitinated proteins ([Figure 6C](#fig6){ref-type="fig"}). Notably, reduction of *Rab7* (*Rab7^Gal4-KO^/+*) improved autophagic clearance in *Vps29* mutant brains.

Lastly, in order to directly visualize lysosomal ultrastructure, we performed transmission electron microscopy (TEM) on retinae and brains from 30-day-old *Vps29^1^/Df* animals ([Figure 7](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). For the retinal studies, we selected conditions for which photoreceptor depolarization is preserved, preceding overt retinal neurodegenerative changes. Indeed, retinal TEM revealed normal numbers and morphology of photoreceptors; however, we documented significantly increased numbers of lysosomes, multivesicular bodies, and autophagic vacuoles. Further, lysosomes were frequently aberrantly enlarged and filled with granular, electron-dense material. These findings are highly suggestive of endolysosomal dysfunction in *Vps29^1^/Df* animals, in agreement with results from other assays. Interestingly, although synaptic transmission is disrupted in these animals (i.e. reduced ERG on/off transients), *Vps29* mutant synaptic terminals in the lamina appeared unremarkable. We observed normal synapse numbers and size, nor did we detect any other apparent evidence of synaptic degeneration. Lastly, we examined TEM of adult brain sections in 30-day-old animals, focusing on cortical regions with densely packed neuronal cell bodies in the dorsal-posterior brain. Consistent with findings in the retina, we discovered significantly increased numbers of aberrant lysosomal structures (multilamellar bodies) in *Vps29* mutants. Collectively, our data indicate that retromer dysfunction following loss of *Vps29* is associated with progressive lysosomal structural and functional degeneration in the aging nervous system.

![Loss of *Vps29* disrupts lysosomal ultrastructure in the brain.\
(**A**) Transmission electron microscopy (TEM) reveals overall preserved photoreceptor morphology, but aberrant endolysosomal structures in retinae from 30-day-old animals lacking *Vps29*. Within each ommatidium (yellow outline), the percentage of photoreceptors (PR) with endolysosomal defects was quantified. Asterisks denote photoreceptors with aberrant endolysosomal structures. Quantification based on n = 30 ommatidia from three animals per genotype. See also [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}. (**B**) At higher magnification, TEM reveals an increase in lysosomes, multivesicular bodies, autophagic vacuoles, and multilamellar bodies in *Vps29* mutant retinae. Lysosomes were frequently observed to be aberrantly enlarged and filled with granular, electron-dense material. (**C**) Distinct endolysosomal structures and/or compartments were quantified in n = 15 photoreceptors, including five photoreceptors from three animals for each genotype. (**D**) Increased numbers of multi-lamellar bodies (asterisks) are observed in cortical neurons from brains 30-day-old animals lacking *Vps29*. Neuronal nuclei ('N') are outlined. Quantification based on cell counts from n = 4 animals (50 cells per brain). See also [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}. Statistical analysis (**A, C, D**) based on Student's t-test. All error bars denote SEM. \*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001.](elife-51977-fig7){#fig7}

Discussion {#s3}
==========

Although strongly implicated in pathogenesis of human neurodegenerative disease, the requirements for retromer in the aging brain remain poorly defined. Our discovery that Vps29 is dispensable for *Drosophila* embryogenesis provides an unexpected opportunity to examine the neuronal consequences of retromer dysfunction in vivo. In the absence of *Vps29*, we document age-dependent impairment in lysosomal proteolysis and autophagy, leading to apparent accumulation of undigested substrates and expansion of the endolysosomal compartment. These cellular changes are accompanied by progressive nervous system dysfunction, with synaptic transmission especially vulnerable. Unexpectedly, Vps29 loss did not affect the expression or stability of other retromer components but influenced their localization via a Rab7- and TBC1D5-dependent regulatory pathway.

VPS29 is required for retromer recruitment via Rab7 and TBC1D5 {#s3-1}
--------------------------------------------------------------

The retromer core initiates cargo recognition and mediates the engagement of other factors that enable proper endocytic trafficking ([@bib12]). However, the differential requirements of each protein within the heterotrimer, including VPS35, VPS26, and VPS29, remain incompletely defined. Structural studies suggest the retromer core has an elongated, flexible structure, with VPS35 serving as a central scaffold, binding VPS26 at its N‐terminus, and VPS29 at its C‐terminus ([@bib24]; [@bib36]; [@bib44]). Consistent with this, loss of VPS35 destabilizes the retromer complex, resulting in reduced VPS26 and VPS29 protein, and this result has been confirmed both in vitro and in vivo ([@bib11]; [@bib42]; [@bib94]). Similarly, knockdown or knockout of *VPS29* in mammalian epithelial cell culture compromises retromer stability, causing loss of the other components ([@bib18]; [@bib28]). Surprisingly, in the absence of Vps29 in *Drosophila*, we found that Vps35 and Vps26 are present at normal levels and remain tightly associated. Instead, Vps35 appears to be mislocalized, shifting from neuropil to soma in the adult brain, and likely disrupting its normal function. Loss of Vps29 also causes apparent hyperactivation (and mislocalization) of Rab7, and a mutation previously shown to disrupt the VPS29-TBC1D5 interaction shows similar phenotypes. Importantly, reduction of Rab7 or overexpression of TBC1D5 potently suppresses *Vps29* loss-of-function. In the adult brain, perinuclear accumulation of Vps35/Rab7 strongly suggests aberrant localization to the late endosome and lysosome, based on the overlap with Arl8 and Spinster. Our in vivo findings recapitulate a two-step molecular mechanism for retromer recruitment and release in neurons ([Figure 8](#fig8){ref-type="fig"}). First, the retromer core is recruited to the endosomal membrane by Rab7-GTP, allowing it to participate in cargo recycling. Subsequently, Vps29 engages TBC1D5, which activates GTP hydrolysis of Rab7, thereby releasing retromer from the endosome. We propose that in the absence of Vps29, retromer is trapped at the endosome membrane in the neuronal cell body, leading to sequestration of functional complexes, and progressive impairment in endocytic trafficking.

![Model for Vps29-dependent retromer recruitment and release.\
In neurons, the retromer core Vp26-Vps35-Vps29 is recruited by Rab7 to the endosomal membrane. Vps29 engages TBC1D5, which promotes inactivation of Rab7 and release of Vps35. In the absence of *Vps29*, the residual retromer complex is trapped at the endosomal membrane.](elife-51977-fig8){#fig8}

The reciprocal interplay and interdependence of retromer and Rab7 that we document in the *Drosophila* nervous system is consistent with prior studies in cell culture ([@bib28]; [@bib41]; [@bib74]). By contrast, the viability of *Vps29* mutants as well as our finding of a more selective, regulatory role for Vps29 in complex localization is unexpected. Unlike the other retromer core subunits, *Vps29* is dispensable for embryogenesis and loss-of-function causes milder retinal phenotypes than *Vps35* or *Vps26*. Moreover, Vps35 overexpression partially rescued selected *Vps29* phenotypes, consistent with a context-dependent, regulatory role. Since Vps35 can weakly bind TBC1D5 ([@bib27]), it may be capable of inactivating Rab7, compensating in part for the absence of Vps29. Our finding that retromer retains some residual activity in flies lacking *Vps29* is reminiscent of results from *C. elegans* ([@bib43]). Moreover, in *S. cerevisiase*, interaction of Vps26 and Vps35 are similarly preserved following loss of *Vps29* ([@bib66]). Importantly, these data suggest that the specific requirement(s) for Vps29---and by extension, retromer activity---may be context dependent, varying with cell-type (e.g. neuron) and/or specific cargo (e.g. Rh1, ceramides, or others). While *Vps29* mutants altered Vps35 subcellular localization in both the adult and larval brains causing relative loss from neuropil regions, potential differences were also noted: the apparent redistribution to soma was only seen in adults. It is also possible that tissue- or species-specific differences might relate to Vps29 participation in other endosomal sorting machinery besides retromer, such as the recently described 'retriever' ([@bib53]); however, this complex has not yet been studied in *Drosophila*. Although we have found that human *VPS29* is capable of functional substitution in flies, it will be important to determine whether our findings also apply in the mammalian nervous system context.

The retromer and endolysosomal trafficking in neurons {#s3-2}
-----------------------------------------------------

Our characterization of flies lacking *Vps29* points to important roles for retromer in both lysosomal and synaptic homeostasis in neurons, interdependent processes that similarly require proper endocytic trafficking. Following *Vps29* loss-of-function, we detected evidence of progressive deterioration in lysosomal function in the adult brain, based on markers of cathepsin maturation and autophagic flux. In both cases, lysosomal function was preserved in newly eclosed animals, but deficits emerged gradually with aging. This result suggests that neurons can initially compensate for retromer insufficiency, whereas adaptive mechanisms may breakdown during aging. Vps35 was strongly mislocalized in 1-day-old animals, suggesting that the manifestation of age-dependent vulnerability likely involves more downstream consequences of retromer dysfunction, such as the accumulation of undigested substrates and resulting lysosomal expansion. Indeed, we found ultrastructural evidence of lysosomal stress in the aged retina and brain, including significantly enlarged lysosomes that were filled with electron-dense and/or multilammellar material. One caveat for interpretation is that TEM data was not included for newly eclosed animals. Nevertheless, our results are consistent with evidence from other experimental systems, that protein and lipid cargoes accumulate gradually in the late endosome and lysosomes in the absence of retromer activity ([@bib39]; [@bib81]; [@bib94]; [@bib97]). Neuronal compensation may entail increasing capacity for substrate turnover, since we found that mature forms of CTSD and markers of autophagic flux were increased in young animals ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). It is also possible that the production of critical membrane proteins dependent on retromer for recycling can be boosted, at least temporarily. The initial resilience of the brain to *Vps29* deficiency that we uncover in *Drosophila* is consistent with relative preservation of autophagy following VPS29 knockout in HeLa cells ([@bib28]). However, there is ample evidence from animal model studies that aging is accompanied by reduced degradative capacity in neurons, which may ultimately contribute to decompensation and increased proteotoxic stress ([@bib52]).

We additionally found that *Vps29* is required for synaptic transmission in both the *Drosophila* retina and larval NMJ, producing a phenotype characteristic of other genes that regulate endocytosis and synaptic vesicle recycling ([@bib3]; [@bib22]). In *Drosophila* S2 cells, Vps35 has been shown to participate in endocytosis ([@bib34]), and our findings confirm and extend prior work ([@bib26]) implicating Vps35 in synaptic structure and function at the NMJ. Whereas both genes appear similarly required for synaptic vesicle endocytosis, loss of *Vps35* but not *Vps29*, also affected spontaneous NMJ activity, causing increased miniature excitatory junction potentials ([@bib26]). This is consistent with our other data suggesting *Vps29* causes overall milder defects. *Vps29* synaptic phenotypes were suppressed by either reduction of Rab7 or overexpression of TBC1D5, similar to our studies of lysosomal phenotypes. Interestingly, ERGs also revealed age-dependent, progressive decline in synaptic transmission. Despite evidence of significant degradation of synaptic function with aging, TEM studies of the *Drosophila* lamina did not reveal overt synaptic structural changes, suggesting a more subtle, predominantly functional defect. Since retromer is present throughout embryonic and larval development, we cannot exclude the possibility of developmental defects due to *Vps29* loss-of-function. Indeed, Vps35 was mislocalized in the *Vps29* mutant larval brain and we documented increased numbers of NMJ synaptic boutons. Nevertheless, the adult brain appeared grossly normal, and electroretinograms and climbing were unaffected in newly eclosed flies.

In sum, we consider two non-exclusive models for potential retromer requirement(s) at the synapse. First, retromer may regulate the trafficking of a key factor required for synaptic membrane endocytosis and/or replenishing of the vesicle pool from synaptic endosomes. Second, *Vps29*-related synaptic dysfunction may instead be related, more broadly, to progressive lysosomal dysfunction. In fact, recent studies have linked synaptic endosomes, lysosomes, and autophagosomes to presynaptic proteostasis, including during vesicle recycling and release ([@bib29]; [@bib95]). For example, another Rab GTPase activating protein, TBC1D24---Skywalker in *Drosophila*---has been shown to regulate synaptic vesicle recycling and quality control via a sorting endosome at NMJ terminals ([@bib15]; [@bib86]). Interestingly, in the *Drosophila* visual system, we found that raising *Vps29* or *Vps35* mutants in the dark rescued retinal degeneration but not synaptic transmission defects, consistent with an uncoupling of retromer requirements in these two spatially distinct processes. Thus, it is possible---if not likely---that synaptic endolysosomal trafficking and function can be regulated independently from that of the neuronal soma.

Additional studies will be required to further dissect and refine our understanding of retromer-dependent synaptic mechanisms. For example, it may be informative to perform neurophysiology studies in mutants for other genes encoding retromer partners (e.g. TBC1D5) or regulators of late endosome-lysosome fusion, such as components of the HOPS complex ([@bib15]; [@bib46]). It will also be important to examine synaptic physiology following retromer loss in the mammalian brain. Retromer components are present at synaptic terminals in mouse primary neuronal culture ([@bib59]; [@bib88]) and in cortical synaptosome preparations ([@bib85]). However, functional studies to date have largely focused on the post-synaptic membrane, where evidence supports retromer requirements for trafficking of glutamatergic and adrenergic neurotransmitter receptors ([@bib9]; [@bib84]).

Retromer and neurodegenerative disease {#s3-3}
--------------------------------------

Retromer dysfunction has been linked to pathogenesis of Parkinson's and Alzheimer's disease ([@bib75]). In both neurodegenerative disorders, synaptic dysfunction is an early pathologic feature, and lysosomal autophagy is also strongly implicated ([@bib25]; [@bib95]). Our findings of age-dependent, progressive synaptic and lysosomal dysfunction in the adult brain of *Drosophila* lacking *Vps29* may therefore be relevant for our understanding of retromer in human diseases. In fact, variants at numerous other genetic loci related to endocytic trafficking and synaptic maintenance have been discovered as risk factors for Alzheimer's disease (*BIN1, PICALM, CD2AP, SORL1*) ([@bib31]) and Parkinson's disease (*SNCA, LRRK2, SH3GL2/EndoA*, *RAB7L1*) ([@bib76]). Genetic links have also recently emerged between Parkinson's disease and lysosomal storage disorders, comprising a heterogeneous group of recessive disorders arising from defects in lysosomal biogenesis and/or function ([@bib101]). These disorders, which can include neurodegenerative features, are characterized by the accumulation of undigested substrates and lysosomal expansion (e.g. glucosylceramide in Gaucher's disease). Importantly, retromer participates in the trafficking of lysosomal hydrolases ([@bib11]; [@bib72]), and in the absence of *Vps29*, we documented accumulation of glucosylceramides along with ultrastructural evidence of brain lysosomal pathology similar to lysosomal storage disorders. Based on mouse models, synaptic dysfunction may be an early manifestation in lysosomal storage disorders similar to *Vps29* mutant flies ([@bib57]; [@bib62]; [@bib71]). Aberrant lysosomal morphology has also been described in both Alzheimer's and Parkinson's disease models ([@bib20]; [@bib78]) and in human postmortem brain ([@bib19]; [@bib64]). Targeting the retromer for therapeutic manipulation in neurodegenerative disease is one promising approach, given the availability of small molecule chaperones that bind Vps29 ([@bib54]; [@bib87]; [@bib100]). However, since the endolysosomal system has many functions, including within neurons and other cell types, it will be essential to pinpoint the specific retromer mechanism(s) responsible for age-related brain diseases.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                                        Source or reference                                             Identifiers                                                                           Additional information
  (species) or resource                                                                                                                                                                                                                                          
  ------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Gene (*D. melanogaster*)              *Vps35*                                                                                                                            FLYB: FBgn0034708                                                                     

  Gene (*D. melanogaster*)              *Vps29*                                                                                                                            FLYB: FBgn0031310                                                                     

  Gene (*D. melanogaster*)              *Vps26*                                                                                                                            FLYB: FBgn0014411                                                                     

  Gene (*D. melanogaster*)              *TBC1D5*                                                                                                                           FLYB: FBgn0038129                                                                     

  Gene (*D. melanogaster*)              *Rab7*                                                                                                                             FLYB: FBgn0015795                                                                     

  Genetic reagent (*D. melanogaster*)   *FRT40A*                                                           Bloomington *Drosophila* Stock Center                           FLYB: FBti000207; RRID:[BDSC_1816](https://scicrunch.org/resolver/BDSC_1816)          *y^1^ w^1118^; P{neoFRT}40A*

  Genetic reagent (*D. melanogaster*)   *ey-FLP; FRT40A*                                                   Bloomington *Drosophila* Stock Center                           FLYB: FBti0015982; RRID:[BDSC_5622](https://scicrunch.org/resolver/BDSC_5622)         *y^d2^, w^1118^, ey-FLP,GMR-lacZ;P{neoFRT}40A,w^+^,cl/CyO,y+*

  Genetic reagent (*D. melanogaster*)   *ey^3.5^-FLP; FRT40A*                                              PMID:[15848801](https://www.ncbi.nlm.nih.gov/pubmed/15848801)                                                                                         *y w ey^3.5^-FLP; FRT40A,cl, w^+^/CyO, Kr \> GFP*

  Genetic reagent (*D. melanogaster*)   *nSyb-Gal4*                                                        Bloomington *Drosophila* Stock Center                           FLYB: FBti0150361; RRID:[BDSC_51635](https://scicrunch.org/resolver/BDSC_51635)       *y^1^ w\*; P{nSyb-GAL4.S}3*

  Genetic reagent (*D. melanogaster*)   *nos-Cas9*                                                         Bloomington *Drosophila* Stock Center                           FLYB: FBti0159183; RRID:[BDSC_54591](https://scicrunch.org/resolver/BDSC_54591)       *y^1^, w\*,M{nos-Cas9.P}ZH-2A*

  Genetic reagent (*D. melanogaster*)   *Vps35^MH20^/CyO*                                                  Bloomington *Drosophila* Stock Center                           FLYB: FBal0221635; RRID:[BDSC_67202](https://scicrunch.org/resolver/BDSC_67202)       *w; P{neoFRT}42D,Vps35^MH20^/CyO, Kr \> GFP*

  Genetic reagent (*D. melanogaster*)   *Df*                                                               Bloomington *Drosophila* Stock Center                           FLYB: FBti0073468; RRID:[BDSC_7491](https://scicrunch.org/resolver/BDSC_7491)         *Df(2L)Exel6004*

  Genetic reagent (*D. melanogaster*)   *UAS-deGradFP*                                                     Bloomington *Drosophila* Stock Center                           FLYB: FBti0147362; RRID:[BDSC_38421](https://scicrunch.org/resolver/BDSC_38421)       *w\*; P{w\[+mC\]=UAS-Nslmb-vhhGFP4}3*

  Genetic reagent (*D. melanogaster*)   *GMR-w-RNAi*                                                       Bloomington *Drosophila* Stock Center                           FLYB: FBti0074622; RRID:[BDSC_32067](https://scicrunch.org/resolver/BDSC_32067)       *GMR-w-RNAi^13D^*

  Genetic reagent (*D. melanogaster*)   *UAS-Spin-GFP*                                                     Bloomington *Drosophila* Stock Center                           FLYB:FBti0148827\                                                                     [*w\*; P{UAS-spin.myc-EGFP}*](http://flybase.org/reports/FBst0039668.html)
                                                                                                                                                                           RRID:[BDSC_39668](https://scicrunch.org/resolver/BDSC_39668)                          

  Genetic reagent (*D. melanogaster*)   *Vps35^GFP^*                                                       This study                                                                                                                                            *Progenitor = w; Vps35^TagRFP-T^;* TagRFP-T cassette was replaced by EGFP

  Genetic reagent (*D. melanogaster*)   *Vps35^RFP^*                                                       PMID:[26700726](https://www.ncbi.nlm.nih.gov/pubmed/26700726)                                                                                         *w; Vps35^TagRFP-T^*

  Genetic reagent (*D. melanogaster*)   *eyFLP;FRT42D*                                                     PMID:[24781186](https://www.ncbi.nlm.nih.gov/pubmed/24781186)                                                                                         *y w,eyFLP,GMR-lacZ; P{neoFRT}42D,w^+^,cl/CyO,Kr \> GFP*

  Genetic reagent (*D. melanogaster*)   *UAS-Vps35*                                                        PMID:[24781186](https://www.ncbi.nlm.nih.gov/pubmed/24781186)                                                                                         *y w; PBac{UAS-Vps35-HA}*

  Genetic reagent (*D. melanogaster*)   *Rab7^EYFP^*                                                       Bloomington *Drosophila* Stock Center                           FLYB: FBst0062545\                                                                    *w^1118^; TI{TI}Rab7^EYFP^*
                                                                                                                                                                           RRID:[BDSC_62545](https://scicrunch.org/resolver/BDSC_62545)                          

  Genetic reagent (*D. melanogaster*)   *Rab7^Gal4-KO^/TM3,Sb*                                             PMID:[24327558](https://www.ncbi.nlm.nih.gov/pubmed/24327558)   FLYB: FBal0294205                                                                     *FRT82B, Rab7^Gal4-KO^/TM3,Sb*

  Genetic reagent (*D. melanogaster*)   *UAS-Venus-Rab7^Q67L^/CyO*                                         PMID:[24327558](https://www.ncbi.nlm.nih.gov/pubmed/24327558)   FLYB: FBal0294206                                                                     *PBac{UAS-Rab7.Q67L.Venus}*

  Genetic reagent (*D. melanogaster*)   *UAS-Venus-Rab7^T22N^/CyO*                                         PMID:[24327558](https://www.ncbi.nlm.nih.gov/pubmed/24327558)   FLYB: FBal0294207                                                                     *PBac{UAS-Rab7.T22N.Venus}*

  Genetic reagent (*D. melanogaster*)   *UAS-Venus-Rab7^WT^/CyO*                                           PMID:[24327558](https://www.ncbi.nlm.nih.gov/pubmed/24327558)   FLYB: FBal0294208                                                                     *PBac{UAS-Rab7.WT.Venus}*

  Genetic reagent (*D. melanogaster*)   *Vps29^1^/CyO,twi-GFP*                                             This study                                                                                                                                            fly strain carrying the *ywing^2+^* dominant marker replacing the gene *Vps29*

  Genetic reagent (*D. melanogaster*)   *Vps29^WT.GFP^/CyO,ubi-GFP*                                        This study                                                                                                                                            fly strain carrying the *Vps29* gene with EGFP...(GGS)4 sequence inserted at the N-terminus of Vps29

  Genetic reagent (*D. melanogaster*)   *Vps29^L152E.GFP^/CyO,ubi-GFP*                                     This study                                                                                                                                            fly strain carrying the *Vps29* gene with EGFP...(GGS)4 sequence inserted at the N-terminus of Vps29. L152 amino acid is mutated to E

  Genetic reagent (*D. melanogaster*)   *Vps29-GR*                                                         This study                                                                                                                                            CH322-128G03 (FLYB: FBcl0761727)

  Genetic reagent (*D. melanogaster*)   *UAS-dVps29*                                                       This study                                                                                                                                            *y w; PBac{UAS-dVps29-myc}*

  Genetic reagent (*D. melanogaster*)   *UAS-hVps29-1*                                                     This study                                                                                                                                            *y w; PBac{UAS-hVps29-1-FLAG}*

  Genetic reagent (*D. melanogaster*)   *UAS-hVps29-2*                                                     This study                                                                                                                                            *y w; PBac{UAS-hVps29-2-FLAG}*

  Genetic reagent (*D. melanogaster*)   *UAS-hVps29-3*                                                     This study                                                                                                                                            *y w; PBac{UAS-hVps29-3-FLAG}*

  Genetic reagent (*D. melanogaster*)   *UAS-dTBC1D5*                                                      This study                                                                                                                                            *y w; PBac{UAS-dTBC1D5-myc}*

  Genetic reagent (*D. melanogaster*)   *w; FRT40A, Vps29^1^/CyO*                                          This study                                                                                                                                            Recombinant between*FRT40A* and *Vps29^1^*

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^,Vps35^GFP^/CyO*                                        This study                                                                                                                                            Recombinant between*Vps35^GFP^* and *Vps29^1^*

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO; Vps29-GR/TM6B*                                    This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO; Rab7^EYFP^/TM6B*                                  This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO; nSyb-Gal4/TM6B*                                   This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO; UAS-dVps29/TM6B*                                  This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO; UAS-hVps29/TM6B*                                  This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO;UAS-dTBC1D5/TM6B*                                  This study                                                                                                                                            Derived by crosses

  Genetic reagent (*D. melanogaster*)   *w;Vps29^1^/CyO;UAS-dVps35/TM6B*                                   This study                                                                                                                                            Derived by crosses

  Antibody                              FITC-conjugated anti-GFP (mouse monoclonal)                        Santa Cruz Biotechnology                                        Cat\# sc-9996 FITC; RRID:[AB_627695](https://scicrunch.org/resolver/AB_627695)        1:100 for IF

  Antibody                              Anti-Rab7 (mouse monoclonal)                                       Developmental Studies Hybridoma Bank                            RRID:[AB_2722471](https://scicrunch.org/resolver/AB_2722471)                          1:100 for IF; 1:1000 for WB

  Antibody                              Anti-Elav (Rat monoclonal)                                         Developmental Studies Hybridoma Bank                            DSHB: Elav-7E8A10; RRID:[AB_528218](https://scicrunch.org/resolver/AB_528218)         1:500 for IF

  Antibody                              Anti-tubulin Clone DM1A (mouse monoclonal)                         Sigma Aldrich                                                   Cat\# T6199; RRID:[AB_477583](https://scicrunch.org/resolver/AB_477583)               1:1000 for WB

  Antibody                              Anti-Vps29 (goat polyclonal)                                       LifeSpan Biosciences                                            Cat\# LS-C55674; RRID:[AB_2214913](https://scicrunch.org/resolver/AB_2214913)         1:2000 for WB

  Antibody                              Anti-Vps35 (Guinea pig polyclonal)                                 This study                                                                                                                                            against C-terminal 338 amino acids of fly Vps35; 1:2000 for WB

  Antibody                              Anti-Vps26 (Guinea pig polyclonal)                                 PMID:[24781186](https://www.ncbi.nlm.nih.gov/pubmed/24781186)                                                                                         1:2000 for WB\
                                                                                                                                                                                                                                                                 1:500 for IF

  Antibody                              Anti-CTSL (mouse monoclonal)                                       R and D Systems                                                 Cat\# MAB22591; RRID:[AB_2087830](https://scicrunch.org/resolver/AB_2087830)          1:1000 for WB

  Antibody                              Anti-CTSD (goat polyclonal)                                        Santa Cruz Biotechnology                                        Cat\# sc-6487; RRID:[AB_637895](https://scicrunch.org/resolver/AB_637895)             1: 500 for WB

  Antibody                              Rabbit anti-Atg8                                                   PMID:[27068460](https://www.ncbi.nlm.nih.gov/pubmed/27068460)                                                                                         1:1000 for WB

  Antibody                              Anti-Polyubiquitinylated conjugates Clone FK1 (mouse monoclonal)   Enzo Life Sciences                                              Cat\# BML-PW8805-0500; RRID:[AB_2052280](https://scicrunch.org/resolver/AB_2052280)   1:1000 for WB

  Antibody                              Rabbit anti-p62/Ref(2)p                                            PMID:[25686248](https://www.ncbi.nlm.nih.gov/pubmed/25686248)                                                                                         1:2000 for WB

  Antibody                              Rabbit anti-Arl8                                                   Developmental Studies Hybridoma Bank                            DSHB Cat\# Arl8, RRID:[AB_2618258](https://scicrunch.org/resolver/AB_2618258)         1:1000 for IF

  Antibody                              Anti-actin clone C4 (mouse monoclonal)                             Millipore                                                       Cat\# MAB1501; RRID:[AB_2223041](https://scicrunch.org/resolver/AB_2223041)           1:1000 for WB

  Antibody                              Cy3-conjugated anti-HRP                                            Jackson ImmunoResearch                                          Cat\# 123-165-021; RRID:[AB_2338959](https://scicrunch.org/resolver/AB_2338959)       1:150 for IF

  Antibody                              Cy3-conjugated Goat anti-mouse IgG                                 Jackson ImmunoResearch                                          Cat\# 115-165-146; RRID:[AB_2338690](https://scicrunch.org/resolver/AB_2338690)       1:500 for IF

  Antibody                              Cy3-conjugated Goat anti-Rat IgG                                   Jackson ImmunoResearch                                          Cat\# 112-165-003; RRID:[AB_2338240](https://scicrunch.org/resolver/AB_2338240)       1:500 for IF

  Antibody                              Mouse anti-goat IgG-HRP                                            Santa Cruz Biotechnology                                        Cat\# sc-2354, RRID:[AB_628490](https://scicrunch.org/resolver/AB_628490)             1:5000 for WB

  Antibody                              Goat anti-mouse IgG-HRP                                            Santa Cruz Biotechnology                                        Cat\# sc-2005; RRID:[AB_631736](https://scicrunch.org/resolver/AB_631736)             1:5000 for WB

  Antibody                              Goat anti-rabbit IgG-HRP                                           Santa Cruz Biotechnology                                        Cat\# sc-2004; RRID:[AB_631746](https://scicrunch.org/resolver/AB_631746)             1:5000 for WB

  Antibody                              Rabbit anti-Glc-Cer                                                Glycobiotech                                                    Cat\# RAS_0010                                                                        1:250 for IF

  Recombinant DNA reagent               Plasmid: pUASTattb_dVps29-myc                                      This study                                                                                                                                            Progenitors: GH25884 (cDNA)

  Recombinant DNA reagent               Plasmid: pUASTattb_dTBC1D5-myc                                     This study                                                                                                                                            Progenitors: BS16827 (cDNA)

  Recombinant DNA reagent               Plasmid: pUASTattb_hVps29-1-FLAG                                   This study                                                                                                                                            Progenitors: OHu00442D (cDNA)

  Recombinant DNA reagent               Plasmid: pUASTattb_hVps29-2-FLAG                                   This study                                                                                                                                            Progenitors: OHu02289D (cDNA)

  Recombinant DNA reagent               Plasmid: pUASTattb_hVps29-3-FLAG                                   This study                                                                                                                                            Progenitors: OHu05688D (cDNA)

  Commercial assay or kit               Subcloning Efficiency DH5α competent cells                         Thermo Fisher Scientific                                        Cat\# 18265017                                                                        

  Commercial assay or kit               Q5 Site-Directed Mutagenesis Kit                                   NEB                                                             Cat\# E0554S                                                                          

  Commercial assay or kit               NEBuilder HiFi DNA Assembly Cloning Kit                            NEB                                                             Cat\# E5520S                                                                          

  Commercial assay or kit               PureLink Genomic DNA Kits                                          Thermo Fisher Scientific                                        Cat\# K182001                                                                         

  Commercial assay or kit               GFP-Trap agarose beads                                             Allele Biotechnology                                            Cat\# ABP-NAB-GFPA100                                                                 

  Chemical compound, drug               2X Laemmli Sample Buffer                                           Bio-Rad                                                         Cat\# 161--0737                                                                       

  Chemical compound, drug               4% paraformaldehyde in 1XPBS                                       ChemCruz                                                        Cat\# sc-281692                                                                       

  Chemical compound, drug               RapiClear                                                          SunJin Lab Co.                                                                                                                                        

  Chemical compound, drug               Vectashield                                                        Vector Laboratories                                             Cat\# H-1000                                                                          

  Chemical compound, drug               Protein A/G agarose                                                Thermo Fisher                                                   Cat\# 20421                                                                           

  Chemical compound, drug               8% glutaraldehyde                                                  EMS                                                             Cat\# 16020                                                                           

  Chemical compound, drug               Cacodylic Acid, Trihydrate Sodium 100 g                            EMS                                                             Cat\# 12300                                                                           

  Chemical compound, drug               EM-grade glutaraldehyde, 25% Aq solution                           EMS                                                             Cat\# 16221                                                                           

  Chemical compound, drug               Osmium tetroxide4% Aq solution                                     EMS                                                             Cat\# 19191                                                                           

  Chemical compound, drug               Paraformaldehyde 16% Aq Solution                                   EMS                                                             Cat\# 15711                                                                           

  Chemical compound, drug               Propylene Oxide                                                    EMS                                                             Cat\# 20411                                                                           

  Chemical compound, drug               Koptec 200 Proof100% ethanol Anhydrous                             VWR                                                             Cat\# 89125--186                                                                      

  Chemical compound, drug               Embed-812                                                          EMS                                                             Cat\# 14901                                                                           

  Chemical compound, drug               NMA                                                                EMS                                                             Cat\# 19001                                                                           

  Chemical compound, drug               DDSA                                                               EMS                                                             Cat\# 13711                                                                           

  Chemical compound, drug               DMP-30                                                             EMS                                                             Cat\# 13600                                                                           

  Chemical compound, drug               Uranyl Acetate                                                     EMS                                                             Cat\# RT22400                                                                         

  Chemical compound, drug               Lead Nitrate                                                       EMS                                                             Cat\# RT17900-25                                                                      

  Chemical compound, drug               Phalloidin 488 nm                                                  ThermoFisher                                                    Cat\# AB_2315147                                                                      

  Chemical compound, drug               FM 1-43FX                                                          Invitrogen                                                      Cat\# F35355                                                                          

  Chemical compound, drug               Western Lightning Plus-ECL                                         PerkinElmer                                                     Cat\# 121001EA                                                                        

  Software, algorithm                   Leica Application Suite X                                          Leica                                                           RRID:[SCR_013673](https://scicrunch.org/resolver/SCR_013673)                          

  Software, algorithm                   LabChart Reader                                                    ADInstruments                                                   <https://www.adinstruments.com/products/labchart-reader>                              

  Software, algorithm                   ImageJ                                                             National Institute of Health                                    RRID:[SCR_003073](https://scicrunch.org/resolver/SCR_003073)                          

  Sequence-based reagent                dVps29-myc-F                                                       This study                                                                                                                                            5'-GAAGATCTTCATGCTCGTTCTGGTACTCGGCGA-3'

  Sequence-based reagent                dVps29-myc-R                                                       This study                                                                                                                                            5'-GCTCTAGACTACAGATCCTCTTCTGAGATGAGTTTTTGTTCGATCTTCTTGTACTCGATGCGCTCCA-3'

  Sequence-based reagent                dTBC1D5-myc-F                                                      This study                                                                                                                                            5'-GAAGATCTATCAACATGACTGTTTGGGGAATAGAAGCCATCA-3'

  Sequence-based reagent                dTBC1D5-myc- R                                                     This study                                                                                                                                            5'-GCTCTAGATCACAGATCCTCTTCTGAGATGAGTTTTTGTTCACTCGATTCGTTTCGATGCCGT-3'

  Sequence-based reagent                hVps29-1-F                                                         This study                                                                                                                                            5'-CCGCCTCGAGGCCACCATGTTGGTGTTGGT-3'

  Sequence-based reagent                hVps29-2-F                                                         This study                                                                                                                                            5'-CCGCCTCGAGGCCACCATGGCTGGGCACA-3'

  Sequence-based reagent                hVps29-3-F                                                         This study                                                                                                                                            5'-CCGCCTCGAGGCCACCATGAGCAGGTGTGCT-3'

  Sequence-based reagent                hVps29-R                                                           This study                                                                                                                                            5'-CTAGTCTAGATTATCACTTATCGTCGTCATCCTTGTAATCAGGT-3'

  Sequence-based reagent                Vps29-P1-F                                                         This study                                                                                                                                            5'-GAACCTGACGTATCCGGAGC-3'

  Sequence-based reagent                Vps29-P1-R                                                         This study                                                                                                                                            5'-TCGCCGATCAGTTGGTACAC-3'

  Sequence-based reagent                Vps29-P2-F                                                         This study                                                                                                                                            5'-CTCGTTCTGGTACTCGGCG-3'

  Sequence-based reagent                Vps29-P2-R                                                         This study                                                                                                                                            5'-ACGAACGAAGGCACCACATT-3'

  Sequence-based reagent                Vps29-P3-F                                                         This study                                                                                                                                            5'-GGCCGCATACATCACATCCT-3'

  Sequence-based reagent                Vps29-P3-R                                                         This study                                                                                                                                            5'-GAATTTGTTGCCGTGCTCGT-3'

  Sequence-based reagent                Vps35-F (Internal control)                                         This study                                                                                                                                            5'-TTGTACCTCCTCATAACAGTGGG-3'

  Sequence-based reagent                Vps35-R (Internal control)                                         This study                                                                                                                                            5'-TCGTTCTCCTCAACCATCACAT-3'

  Other                                 Leica SP8 confocal microscope                                      Leica                                                                                                                                                 

  Other                                 Leica DM 6000 B system                                             Leica                                                                                                                                                 

  Other                                 Zeiss LSM 880 with Airyscan                                        Zeiss                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fly stocks and husbandry {#s4-1}
------------------------

A complete list of fly strains used in this study is included in the Key Resources Table. Detailed information on experimental genotypes can also be found in figures and figure legends. The *Vps29^1^* null allele was generated using CRISPR/Cas9-mediated gene replacement, as previously described ([@bib38]). Briefly, a dominant marker *ywing^2+^* flanked by homology arms on each side, along with sgRNA expression plasmids, were injected into embryos expressing Cas9 (*y^1^,w\*,M{nos-Cas9.P}ZH-2A*). G0 animals were next crossed to *y w*, and progeny were screened for the presence of the *yellow^+^* wing marker to identify *Vps29^1^* (*Vps29^ywing2+^*). Studies of *Vps29* mutant flies used either *Vps29^1^* homozygotes or the transheterozygous genotype, *Vps29^1^/Df(2L)Exel6004* (referred to as *Vps29^1^/Df*). To generate the *Vps29* genomic rescue strain, a 23 kb P\[acman\] genomic fragment (CH322-128G03) including the *Vps29* locus was injected into *y,w,ΦC31; VK33 attP* embryos, followed by selection of F1 transformants. All studies using the transgenic *Vps29* BAC examined the genomic rescue construct (*GR*) in heterozygosity (either *Vps29^1^;GR/+* or *Vps29^1^/Df;GR/+*).

In order to generate the *Vps29^WT.GFP^* and *Vps29^L152E.GFP^* alleles, we again used the CRISPR/Cas9 gene-replacement system, starting with the *Vps29^1^* strain. The GFP coding sequence was cloned in-frame and proximal to the *Vps29* cDNA using NEBuilder HiFi DNA Assembly Cloning Kit (NEB). Using Q5 Site-Directed Mutagenesis Kit (NEB), the L152E mutation was introduced to the *GFP::Vps29* plasmid. As above, the *GFP::Vps29* or *GFP::Vps29^L152E^* constructs were each injected into *y^1^ M{nos-Cas9.P}ZH-2A w\*; Vps29^1^/CyO* flies. G0 flies were crossed to *y w*, and F1 progeny were screened for loss of the *yellow^+^* marker to establish the *Vps29^WT.GFP^* and *Vps29^L152E.GFP^* strains. The sequence of all CRISPR/Cas9-generated strains were confirmed by genomic PCR followed by Sanger sequencing. Genomic DNA from a single fly was prepared using 'squish buffer' (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 25 mM NaCl, and 0.2 mg/ml Proteinase K). Total genomic DNA was extracted using the PureLink Genomic DNA Kit (Thermo Fisher Scientific). PCR primers used for additional confirmation of the *Vps29^1^* allele ([Figure 1B](#fig1){ref-type="fig"}) are listed in the Key Resources Table.

As part of this study, we also generated transgenic strains carrying *UAS-dVps29-myc*, *UAS-dTBC1D5-myc*, and *UAS-hVps29-FLAG*. The full-length *Drosophila* Vps29 cDNA (*Drosophila* Genomics Resource Center (DGRC) plasmid: GH25884) was cloned proximal to *c-myc* coding sequencing, using primers *dVps29-myc-F* and *dVps29-myc-R* (Key Resources Table). The full-length cDNA for *TBC1D5* (DGRC plasmid: BS16827) was similarly cloned proximal to the *c-myc* coding sequencing using primers *dTBC1D5-myc-F* and *dTBC1D5-myc-R*. The *Vps29-myc* and *TBC1D5-myc* PCR products were each digested with BglII and XbaI restriction enzymes (NEB) and ligated to the *pUAST-attB* vector using T4 ligase (NEB). Plasmids containing FLAG-tagged Human VPS29 cDNAs (OHu00442D, OHu02289D, and OHu05688D, respectively) were obtained from GenScript. For PCR cloning, we used *hVps29-R* along with each of the following: *hVps29-1-F* for hVps29 transcript variant 1 (NM_016226.4), *hVps29-2-F* for hVps29 transcript variant 2 (NM_057180.2), and *hVps29-3-F* for hVps29 transcript variant 3 (NM_001282150.1). PCR products were digested by XhoI and XbaI restriction enzymes (NEB), and then ligated to the *pUAST-attB* vector. The resulting constructs were purified, verified by Sanger DNA sequencing, and injected into *y,w,ΦC31; VK33* embryos to generate transgenic flies. The generation of *w;Vps35^TagRFP-T^* (*Vps35^RFP^*) with a Rippase-switchable TagRFP-T to GFP tag was described in [@bib33]. *w;Vps35^GFP^* was generated by crossing *Vps35^RFP^* to *bam-Gal4;;UAS-Rippase::PEST \@attP2* flies to isolate germline ripouts of the TagRFP-T cassette, leaving a C-terminal EGFP knockin.

All *Drosophila* crosses were raised on molasses-based food at 25°C unless otherwise noted. To induce neuronal specific knockdown of Vps35^GFP^, we used the deGradFP system ([@bib6]; [@bib60]). Crosses were established and maintained at 18°C, and following eclosure, adults were shifted to 29°C for 7 days before brain dissection.

Histology and immunofluorescence {#s4-2}
--------------------------------

For histology, *Drosophila* heads were fixed in 8% glutaraldehyde (Electron Microscopy Sciences) at 4°C for 6 days and embedded in paraffin. Frontal (5 μm) sections were cut using a Leica Microtome (RM2245), mounted on slides, and stained with hematoxylin and eosin. For whole mount brain immunostaining, adult fly brains were dissected in 1X PBS and fixed at 4°C overnight in 4% paraformaldehyde in 1X PBS (sc-281692, ChemCruz). Fixed brains were permeabilized with 2% PBST (1X PBS+2% Triton X-100) at 4°C for 20 hr, and then vacuumed (Nalgene) at room temperature for 1 hr. Brains were incubated with the primary antibodies at 4°C for 2 days, followed by secondary antibody incubation for 1 day at 4°C, then mounted in RapiClear (SunJin Lab Co.). For NMJ staining, wandering third instar larvae were dissected in Hemolymph-Like 3 (HL3) solution without calcium (110 mM NaCl, 5 mM KCl, 10 mM NaHCO~3~, 10 mM MgCl~2~, 5 mM trehalose, 30 mM sucrose, and 5 mM HEPES, pH 7.2), fixed in 100% methanol at room temperature for 20 min, washed in 0.3% PBST, and blocked for 1 hr in 0.3% PBST containing 5% normal goat serum. Tissues were incubated with primary antibody overnight at 4°C, followed by secondary antibodies at room temperature for 2 hr, and mounted using Vectashield (Vector Laboratories) prior to imaging. All NMJ studies focused on muscles 6/7, abdominal section 2 and 3. To quantify GFP (Vps35) intensity within NMJ synaptic boutons, confocal regions of interest (ROIs) were determined using the Imaris (Bitplane) 'surface' tool to select HRP-positive regions. Identical parameters for defining HRP surfaces were applied for all samples. Mean GFP signal intensity within the ROI encompassing the synaptic area was normalized to HRP volume (μm^3^). For fly retina staining, fly heads were fixed after the removal of proboscis in 3.7% formaldehyde in PBS at 4°C overnight. Fixed retinae were dissected and blocked in 0.1% PBST containing 5% natural donkey serum at room temperature for 1 hr, followed by primary antibody incubation for 2 days at 4°C and secondary antibody incubation for 2 hr at room temperature. Primary antibodies were used at following dilutions in 0.3% PBST: FITC-conjugated anti-GFP (sc-9996 FITC, 1:100, Santa Cruz Biotechnology, RRID:[AB_627695](https://scicrunch.org/resolver/AB_627695)), Mouse anti-Rab7 (1:100, DSHB, RRID:[AB_2722471](https://scicrunch.org/resolver/AB_2722471)), Rat anti-Elav (7E8A10,1:500, DSHB, RRID:[AB_528218](https://scicrunch.org/resolver/AB_528218)), Rabbit anti-GlcCer (1:250, Glycobiotech); Cy3-conjugated anti-HRP (1:150, Jackson ImmunoResearch); Rabbit anti-Arl8 (1:1000, DSHB, RRID:[AB_2618258](https://scicrunch.org/resolver/AB_2618258)); Guinea pig anti-Vps26 (1:500, [@bib94]). For secondary antibodies, we used Cy3-conjugated goat anti-mouse or anti-Rat IgG, and Alexa 647-conjugated goat anti-Rabbit or anti-Guinea pig IgG (1:500, Jackson ImmunoResearch). Confocal microscopy images were acquired with a Model LSM 880 confocal system (Carl Zeiss).

Western blot analysis and immunoprecipitation {#s4-3}
---------------------------------------------

For western blots, adult fly heads or whole larvae were homogenized in 2X Laemmli Sample Buffer (Bio-Rad) with 5% β-mercaptoethanol (Calbiochem) using a pestle (Argos Technologies). The lysates were heated at 95°C for 5 min, followed by centrifugation at 21,130 × *g* at 4°C for 15 min before SDS-PAGE analysis. Samples were loaded into 12% Bis-Tris gels (Invitrogen), separated by SDS-PAGE. For immunoprecipitation of Vps35^GFP^, 300 fly heads from 1- to 2 day-old animals were homogenized on ice in 700 μL of lysis buffer containing 10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, and 1X complete protease inhibitor (Roche). Homogenized samples were centrifugated at 21,130 × *g* for 30 min at 4°C. 3% (by volume) of the supernatant were reserved for total protein input. The remaining supernatant was incubated for 1 hr at 4°C with 50 μL of protein A/G agarose slurry (Thermo Fisher) to reduce non-specific binding. Following pre-clearing, the lysate was incubated for 3 hr at 4°C with 35 μL of GFP-Trap agarose beads (Allele Biotechnology) with mild agitation. The beads were washed three times with lysis buffer, boiled in 70 μL of 2X Laemmli sample buffer (Biorad), and subjected to SDS-PAGE (BOLT12% Bis-Tris Gel, Invitrogen). Gels were transferred to PVDF membrane (Millipore), and blocked in 5% bovine serum albumin (Sigma) in 1X TBST (Tris-buffered saline + 0.1% Tween-20). We used the following primary antibodies and dilutions: mouse anti-tubulin (DM1A, Sigma Aldrich, RRID:[AB_477583](https://scicrunch.org/resolver/AB_477583)), 1∶1000; mouse anti-Rab7 (DSHB, RRID:[AB_2722471](https://scicrunch.org/resolver/AB_2722471)), 1∶1000; Goat anti-Vps29 (LS-C55674, LifeSpan Biosciences, RRID:[AB_2214913](https://scicrunch.org/resolver/AB_2214913)),1:2000; Guinea pig anti-Vps26 ([@bib94]), 1:2000; Guinea pig anti-Vps35 (see below), 1:2000; Mouse anti-CTSL (clone 193702, MAB22591, R and D Systems, RRID:[AB_2087830](https://scicrunch.org/resolver/AB_2087830)), 1:2000; Goat anti-CTSD (sc-6487, Santa Cruz, RRID:[AB_637895](https://scicrunch.org/resolver/AB_637895)): 1:500, Rabbit anti-p62/Ref(2)p ([@bib70]), 1:2000; Rabbit anti-Atg8 ([@bib5]), 1:1000; Mouse anti-GFP (B-2, Santa Cruz, RRID:[AB_627695](https://scicrunch.org/resolver/AB_627695)), 1:1000; Mouse anti-actin (C4, Millipore, RRID:[AB_2223041](https://scicrunch.org/resolver/AB_2223041)), 1:1000; Mouse anti-Polyubiquitinylated proteins (clone FK1, Enzo, RRID:[AB_2052280](https://scicrunch.org/resolver/AB_2052280)), 1:1000. HRP-conjugated secondary antibodies were used at 1:5000. Antibodies against *Drosophila* Vps35 were generated by immunization of guinea pigs with a bacterially expressed peptide comprising the C-terminal 338 amino acids of Vps35. Bacterial expression as a GST fusion protein was facilitated by the pGEX 6 P-2 vector. The GST tag was used for protein purification and was cleaved off using PreScission Protease (GE Healthcare Life Sciences) prior to immunization.

Survival and climbing assays {#s4-4}
----------------------------

For survival analyses, around 200 flies per genotype (approximately equal numbers of females and males) were aged in groups of no more than 30 flies per vial, transferring to fresh vials and food every 2--3 days. For the startle-induced negative geotaxis assay (climbing), four to five groups consisting of approximately 15 flies each were placed in a plastic cylinder. Flies were gently tapped to the bottom of the cylinder, and locomotor activity was videotaped and quantified as the percentage of animals climbing past the 9 cm line within a 15 s interval.

Electroretinogram (ERG) {#s4-5}
-----------------------

All crosses were initially maintained in the dark to prevent flies from being exposed to light before eclosion. Newly-eclosed adults were either shifted to a 12 hr light/dark cycle (3,000 lux for light exposure) or maintained in light-sealed boxes for constant darkness. During aging, the positions of light-exposed vials were randomly shuffled within racks. ERG recordings were performed as previously described ([@bib8]). In brief, adult flies were anesthetized and glued to a glass slide, with electrodes placed on the corneal surface and the thorax. Flies were maintained in the dark for at least 1 min prior to stimulation using a train of alternating light/dark pulses. Retinal responses were recorded and analyzed using LabChart software (ADInstruments). At least eight flies were examined for each genotype and timepoint.

NMJ electrophysiology and FM 1--43 dye studies {#s4-6}
----------------------------------------------

Animals were dissected at the wandering third instar stage in HL3 buffer (above), without addition of calcium. Electrophysiologic recordings were performed with 0.5 mM extracellular Ca^2+^ buffer concentrations, as described in [@bib63]. Larval motor axons were severed and miniature excitatory junction potentials (mEJPs) were recorded from muscle 6 of abdominal segments A2 and A3 for 2 min. EJPs were evoked at 0.2 Hz. EJPs and mEJPs were analyzed using pClamp6 (Molecular Devices) and Mini Analysis Program (Synaptosoft) software, respectively. High-frequency stimulation was recorded at 10 Hz for 10 min. The recorded EJP data were binned at 0.5 min intervals and normalized to the average EJP. EJP amplitudes were corrected for nonlinear summation as previously described ([@bib48]). The FM 1--43 dye uptake assay was performed as described in [@bib91]. Larval NMJ preparations were stimulated for 2 min in dark conditions using HL3 buffer containing 90 mM K^+^, 1.5 mM Ca^2+^, and 4 µM FM 1--43 dye. Larval preparations were subsequently washed five times with HL3 solution (without 90 mM K^+^ and calcium), and FM dye uptake was imaged using a Leica Sp8 confocal system. Signal intensity of FM dye per bouton was normalized to each bouton area. Six boutons were sampled per animal. For each genotype, 7--11 animals were assayed.

Transmission Electron Microscopy (TEM) {#s4-7}
--------------------------------------

For analysis of adult eye ultrastructure, fly heads were dissected by removing proboscis and air sacs, then severed from the thorax. For analysis of central brain ultrastructure, fly heads were dissected by removing cuticles and eyes to ensure complete penetration of fixative, leaving each head affixed to the thorax. All samples were processed for TEM as previously described ([@bib8]) using a Ted Pella Bio Wave processing microwave with vacuum attachment. Briefly, dissected samples were fixed (4% paraformaldehyde, 2% glutaraldehyde, and 0.1 M sodium cacodylate, pH 7.2) at 4°C for 48 hr, and then submerged in 1% osmium tetroxide for 45 min. The fixed samples were dehydrated using an ethanol series followed by propylene oxide, and then embedded using Embed-812 resin (EMS). For brain samples, each head was removed carefully from the thorax prior to embedding. Transverse sections of brains (50 nm) and tangential sections of eyes (50 nm) were prepared with a Leica UC7 microtome, and post-stained with 1% uranyl acetate and 2.5% lead citrate. All TEM images were acquired using a JEOL 1010 Transmission Electron Microscope. TEM images of photoreceptor sections were prepared from three different animals per genotype. TEM images of brain sections were prepared from four animals per genotype. Images were acquired from the dorsal-posterior cortical brain region ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}), including at least 50 cells per brain.

Quantification and statistics {#s4-8}
-----------------------------

Confocal images were processed and analyzed using ImageJ software (NIH). Sample size for all comparisons is included in each figure legend (also noted above). For survival curves, we performed log-rank test with Bonferroni\'s correction. For other statistical analysis, we performed two-tailed, unpaired t-tests or Analysis of Variance (ANOVA) followed by Tukey's post-hoc test for multiple comparisons, as specified in all figure legends. The significance threshold for all analyses was set to p\<0.05. Otherwise, results are noted as 'not significant' (n.s.). Error bars in all analyses represent the standard error of the mean (SEM).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Retromer subunit, VPS29, regulates synaptic transmission and is required for endolysosomal function in the aging brain\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Ole Kjærulff (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript submitted by Ye et al. reports, for the first time, the effect of deleting the *Drosophila* gene encoding a core retromer component, *Vps29*. Intriguingly, in the adult brain this causes a striking redistribution of another core component, Vps35, from the neuropil to somata. Also, in *Vps29* mutants, synaptic endocytosis is compromised at the larval neuromuscular junction. Moreover, with aging the retromer insufficiency associated with *Vps29* loss elicits progressive endolysosomal dysfunction, with ultrastructural evidence of impaired substrate clearance and lysosomal stress.

The manuscript is of high quality. It contains novel and interesting results that should be of broad interest, and the preparation is thorough. Overall, we believe that the results provide a promising starting point for publication in *eLife*. However, we also feel that stronger attempts could be made to substantiate the claims made by the authors and to obtain deeper mechanistic insights.

Essential revisions:

1\) In Figure 8 (bottom), the authors propose a molecular model that posits that, in *Vps29* mutants, the two other retromer core components Vps35 and Vps26 should co-localize on endosomes, trapped by Rab7-GTP. Although this model is well in accordance with the evidence obtained from genetic experiments, we feel that more data are required to substantiate it. Specifically, more could be done to characterize the distribution and predicted co-localization of Vps35-GFP and the Rab7 immunosignal at the subcellular (organellar) level, rather than just demonstrating the co-localization at the cellular level in the antennal lobe perinuclei as in the present manuscript. Investigating the subcellular (co-)localization could be done generally, e.g. in the larval CNS or in more \"defined\" systems, such as the large somata associated with some peptidergic neurons (using, for example, the c929-Gal4 or the CCAP-Gal4 driver).

Another well-suited substrate for these experiments might be the larval garland cells. Although Rab7-GTP and Vps35 in the *Vps29* nulls are likely to accumulate primarily on late endosomes, it would be desirable -- and the authors should decide if they can reasonably do this -- if this could be verified using independent markers for late endosomes/lysosomes, such as Rab9, LrrK, Spinster, or LAMP1.

2\) The authors demonstrate in *Vps29* nulls both that synaptic endocytosis is compromised at the third instar larval NMJ and that Vps35 redistributes/mislocalizes from the neuropil to somata in the adult brain. To explore in more depth -- in the same neuronal population, in which synaptic effects were evaluated -- the possible mechanistic link between retromer mislocalization and synaptic dysfunction, we are curious to know if, in *Vps29* nulls, Vps35 also mislocalizes in larval motor neurons (Vps35 is stated to be present at the pre-synapse at the NMJ). Would Vps35 redistribute away from the pre-synapse (and possibly from axons) and accumulate in the cell bodies also in these neurons? This experiment should be feasible, e.g. by constructing UAS-Vps35\[GFP\], *Vps29*\[1\]; D42-Gal4/+ larvae, where D42-Gal4 is a motor neuron driver located on the third.

3\) The authors also point out that the lysosomal function is perturbed in retromer mutants. It is possible that the observed perturbation of endocytosis and synaptic vesicle recycling are indirect effects of lysosomal dysfunction rather than due to a direct requirement for retromer during the earlier stages of the endosomal pathway. The authors could discuss this point and, perhaps, could test this by doing high-frequency stimulation or at least FM1-43 uptake experiments in mutants that abrogate LE-lysosome fusion (such as null mutations for the HOPS complex components Vps39 or Lt/Vps41 -- which are viable until early pupal stages). A milder phenotype in mutants that specifically perturb lysosomal function compared to retromer mutants would demonstrate that retromer\'s effect on endocytosis is directly due to its function in the upstream part of the endosomal pathway.

4\) The use of different mutants is not always clear. Sometimes, the mutant over deficiency is used and not the homozygous viable mutant generated by the authors. Is there a specific reason or difference in the phenotypes, e.g. background mutations on the CRISPR chromosome?

The CRISPR null mutant seems to have stronger phenotypes in some cases, like the retinal degeneration phenotype after 20 days shown in Figure 1---figure supplement 1B and or the declined climbing ability of aged flies shown in Figures 3A and B, than the mutant/Df. Especially the retinal degeneration phenotype (see Figure 1---figure supplement 1B) seems to be more pronounced. An experimental comparison of the phenotypes, including rescue, using the same assay (e.g. but not necessarily, TEM) would be useful to assess defects due to *Vps29* independent of the background.

5\) Figure 1F and subsection "*Vps29* is required for age-dependent retinal function", second paragraph: In the depolarization graph, for flies raised 10 days in the dark, the difference between control and null mutant looks comparable to the measured difference at 10 days light-dark stimulation, which is highly significant with three asterisks. What is the precise p-value for the \"dark flies\"? Is the missing significance here due to a high variance in data points, although this is not shown by the error bar? If the variance is high, why were only 6-8 flies tested here? Here, the single data points should be shown and the n number of flies tested for ERG needs to be increased to at least double the number of flies tested.

Furthermore, the amplitude of the depolarization of null mutant flies raised in dark for 10 days is lower than the amplitude for the LD flies. Although, in the manuscript, this is described as a \"rescued phototransduction\". Is the amplitude of \"dark flies\" consistently lower than the LD flies? More flies (again at least double the number of flies tested before) should be tested here to clarify significance.

In general, there is a marked discrepancy for the amplitude between the example data in E and the population data in 1F, both for *Vps29* and Vps35 mutants when looking across the three experimental conditions D1-dark, D1 12h-LD, and D10-dark

6\) Figure 3A and B: In A, the percentage of mutant/Df flies passing 9 cm in 15 sec is around 40%. While in B, the percentage of null mutant flies (VPS291; *nsyb-Gal4*) is roughly 10%, although being of the same age as the flies tested in A. How can this significant difference be explained and why weren\'t the null mutant flies also tested at 2 and 10 days, if they are so different than mutant/Df flies? The authors should test the null mutant flies also for 2 and 10 days to check for any stronger behavior effects compared to the mutant over deficiency flies.

10.7554/eLife.51977.sa2

Author response

> Essential revisions:
>
> 1\) In Figure 8 (bottom), the authors propose a molecular model that posits that, in Vps29 mutants, the two other retromer core components Vps35 and Vps26 should co-localize on endosomes, trapped by Rab7-GTP. Although this model is well in accordance with the evidence obtained from genetic experiments, we feel that more data are required to substantiate it. Specifically, more could be done to characterize the distribution and predicted co-localization of Vps35-GFP and the Rab7 immunosignal at the subcellular (organellar) level, rather than just demonstrating the co-localization at the cellular level in the antennal lobe perinuclei as in the present manuscript. Investigating the subcellular (co-)localization could be done generally, e.g. in the larval CNS or in more \"defined\" systems, such as the large somata associated with some peptidergic neurons (using, for example, the c929-Gal4 or the CCAP-Gal4 driver).
>
> Another well-suited substrate for these experiments might be the larval garland cells. Although Rab7-GTP and Vps35 in the Vps29 nulls are likely to accumulate primarily on late endosomes, it would be desirable -- and the authors should decide if they can reasonably do this -- if this could be verified using independent markers for late endosomes/lysosomes, such as Rab9, LrrK, Spinster, or LAMP1.

In order to address these questions and further substantiate our findings, we have performed a number of additional studies, as requested. First, we have performed additional stainings in the adult brain, including 2 independent markers for the late endosome/lysosome, Arl8 and Spinster-GFP. We find that Arl8 is also increased in *Vps29* mutants, and that these proteins show overlapping perinuclear localization in the antennal lobe, along with Vps35 (Figure 4---figure supplement 3A). Rab7 and Arl8 function co-ordinately in late endosome-lysosome fusion (Jongsma et al., 2020; Marwaha et al., 2017). In addition, higher-power imaging of several large neurons in the posterior central brain reveals that the increased Rab7- and Arl8-positive signal assumes a punctate, cytoplasmic distribution that further co-stains with Spinster-GFP (*nsyb-Gal4\>UASSpinster-GFP*) (Figure 4---figure supplement 3B). We have added relevant text to the Results (subsection "*Vps29* interacts with Rab7 and *TBC1D5*", first paragraph) and Discussion (subsection "VPS29 is required for retromer recruitment via Rab7 and *TBC1D5*", first paragraph). We believe these data further support our model that residual retromer components are trapped with Rab7 at the late endosome/lysosome. As requested, we also examined staining in other regions. In the adult retina of *Vps29* mutants, we found that Vps35, Vps26, and Rab7 are increased in the cortex of the lamina where neuronal cell bodies are concentrated. Lastly, we have also performed additional stainings in larval brain and at the larval NMJ. In the larval brain, we document a striking loss of Vps35-GFP staining in the neuropil regions, and more subtle but consistent reduction of Vps35GFP at synaptic boutons. Although we were not able to appreciate similar redistribution to the neuronal soma in larvae, this may be due to differences in assay sensitivity or mechanisms in the larval vs. adult nervous system. The new data on Vps35 localization is discussed in the Results (subsection "*Vps29* regulates retromer localization and is required in the aging nervous system", last paragraph) and Discussion (subsection "VPS29 is required for retromer recruitment via Rab7 and *TBC1D5*", last paragraph), and is shown in Figure 4---figure supplement 1B and Figure 4---figure supplement 2. Overall, our results support an important role for *Vps29* in retromer localization within neurons.

> 2\) The authors demonstrate in Vps29 nulls both that synaptic endocytosis is compromised at the third instar larval NMJ and that Vps35 redistributes/mislocalizes from the neuropil to somata in the adult brain. To explore in more depth -- in the same neuronal population, in which synaptic effects were evaluated -- the possible mechanistic link between retromer mislocalization and synaptic dysfunction, we are curious to know if, in Vps29 nulls, Vps35 also mislocalizes in larval motor neurons (Vps35 is stated to be present at the pre-synapse at the NMJ). Would Vps35 redistribute away from the pre-synapse (and possibly from axons) and accumulate in the cell bodies also in these neurons? This experiment should be feasible, e.g. by constructing UAS-Vps35\[GFP\], Vps29\[1\]; D42-Gal4/+ larvae, where D42-Gal4 is a motor neuron driver located on the third.

As described above, we have examined the localization of Vps35-GFP at the larval NMJ in *Vps29* mutant animals, and we have newly added our results showing a reduction of the synaptic staining (Figure 4---figure supplement 2B and subsection "*Vps29* regulates retromer localization and is required in the aging nervous system", last paragraph). The striking reduction of Vps35-GFP in the larval brain neuropil (Figure 4---figure supplement 2A) is also consistent, but we do not detect a concomitant enrichment of Vps35 in the motor neuron cell bodies. While it is possible that these incongruities might be resolved with additional studies, such as with tissue specific manipulation with D42-Gal4, we were not able to feasibly undertake such experiments given the time constraints. In our original manuscript, we explicitly separated discussion of the larval NMJ synaptic studies from those performed in the adult brains, given uncertainty as to whether the *Vps29* loss-of-function phenotypes have similar explanations. However, our new data support the possibility that retromer mislocalization indeed contributes to both.

> 3\) The authors also point out that the lysosomal function is perturbed in retromer mutants. It is possible that the observed perturbation of endocytosis and synaptic vesicle recycling are indirect effects of lysosomal dysfunction rather than due to a direct requirement for retromer during the earlier stages of the endosomal pathway. The authors could discuss this point and, perhaps, could test this by doing high-frequency stimulation or at least FM1-43 uptake experiments in mutants that abrogate LE-lysosome fusion (such as null mutations for the HOPS complex components Vps39 or Lt/Vps41 -- which are viable until early pupal stages). A milder phenotype in mutants that specifically perturb lysosomal function compared to retromer mutants would demonstrate that retromer\'s effect on endocytosis is directly due to its function in the upstream part of the endosomal pathway.

We agree with the reviewers that either or both interpretations are consistent with our experimental data. We have attempted to discuss these alternative models at length in the Discussion (subsection "The retromer and endolysosomal trafficking in neurons"), first presenting the evidence in support of primary lysosomal dysfunction followed by the data that supports a synaptic role. We then discuss the 2 alternative mechanistic models "head-to-head". In our revisions we have made edits to further clarify this discussion, and we have added text to emphasize potential future experimental approaches that might further differentiate between these possibilities. We are eager to pursue this line of investigation, as suggested by reviewers; however, given the time constraints, we were not able to complete and include these experiments as part of this revision.

> 4\) The use of different mutants is not always clear. Sometimes, the mutant over deficiency is used and not the homozygous viable mutant generated by the authors. Is there a specific reason or difference in the phenotypes, e.g. background mutations on the CRISPR chromosome?
>
> The CRISPR null mutant seems to have stronger phenotypes in some cases, like the retinal degeneration phenotype after 20 days shown in Figure 1---figure supplement 1B and or the declined climbing ability of aged flies shown in Figures 3A and B, than the mutant/Df. Especially the retinal degeneration phenotype (see Figure 1---figure supplement 1B) seems to be more pronounced. An experimental comparison of the phenotypes, including rescue, using the same assay (e.g. but not necessarily, TEM) would be useful to assess defects due to Vps29 independent of the background.

As noted, we have utilized both the *Vps29^1^*homozygous and *Vps29^1^ / Df* genotypes in our studies, along with a genomic rescue (BAC transgenic) strain (GR) to ensure specificity of all phenotypes studied. As is standard for careful genetic analyses, in several cases, we have examined both genotypes as a further control for potential genetic background effects, including the possibility of unknown linked mutations on the *Vps29^1^*chromosome. In order to address the valid concern raised by the reviewers, we have carefully repeated the locomotor (climbing) assay, including both *Vps29^1^*homozygous and *Vps29^1^ / Df* genotypes, along with key controls (*Vps29^1^; GR/+* and *Vps29^1^ / Df; GR/+*). The new results (Figure 3A) indeed confirm that the *Vps29^1^*homozygote genotype manifests a stronger locomotor dysfunction phenotype (p\<0.01 in comparisons at 20 days). Importantly however, both genotypes are fully rescued by the genomic BAC transgene. We conclude that while the *Vps29^1^* chromosome may contain an enhancer (or the Df chromosome, a suppressor), our rescue data confirms the specificity of the climbing phenotype for loss of *Vps29 --* similar to other phenotypes of interest in our study. We have added text to the Results to make this interpretation clearer (subsection "*Vps29* regulates retromer localization and is required in the aging nervous system", first paragraphs), and our revision also explicitly denotes the genotypes for key experiments to avoid any ambiguity in the manuscript text.

> 5\) Figure 1F and subsection "Vps29 is required for age-dependent retinal function", second paragraph: In the depolarization graph, for flies raised 10 days in the dark, the difference between control and null mutant looks comparable to the measured difference at 10 days light-dark stimulation, which is highly significant with three asterisks. What is the precise p-value for the \"dark flies\"? Is the missing significance here due to a high variance in data points, although this is not shown by the error bar? If the variance is high, why were only 6-8 flies tested here? Here, the single data points should be shown and the n number of flies tested for ERG needs to be increased to at least double the number of flies tested.
>
> Furthermore, the amplitude of the depolarization of null mutant flies raised in dark for 10 days is lower than the amplitude for the LD flies. Although, in the manuscript, this is described as a \"rescued phototransduction\". Is the amplitude of \"dark flies\" consistently lower than the LD flies? More flies (again at least double the number of flies tested before) should be tested here to clarify significance.
>
> In general, there is a marked discrepancy for the amplitude between the example data in E and the population data in 1F, both for Vps29 and Vps35 mutants when looking across the three experimental conditions D1-dark, D1 12h-LD, and D10-dark

We thank the reviewers for their careful review of these data, and we apologize for the confusion, which is the result of an unfortunate -- and embarrassing -- error in compositing of Figure 1F. For our manuscript figures, all graphical elements including labels, axes, and statistical notation (indicating significance) are prepared in Adobe Illustrator, and hyperlinks are embedded to extract the original experimental data charts from the separate application, Graphpad. In our original manuscript submission, these hyperlinks for Figure 1F were incorrect, such that results from the wrong electroretinogram (ERG) experiment were displayed for the data labeled as Day 10 (both 12h-LD and Dark conditions); the Day 1 data is correctly labeled. This error was missed because it was inadvertently introduced in preparing figures for the final submission, but was not present in an earlier circulated version that was reviewed more carefully. This figure "typesetting" error did not impact the results text -- which were a valid and correct reporting of all findings.

> 6\) Figure 3A and B: In A, the percentage of mutant/Df flies passing 9 cm in 15 sec is around 40%. While in B, the percentage of null mutant flies (VPS291; nsyb-Gal4) is roughly 10%, although being of the same age as the flies tested in A. How can this significant difference be explained and why weren\'t the null mutant flies also tested at 2 and 10 days, if they are so different than mutant/Df flies? The authors should test the null mutant flies also for 2 and 10 days to check for any stronger behavior effects compared to the mutant over deficiency flies.

As addressed fully in the response to question \#4, above, we have now repeated the locomotor studies including both genotypes (*Vps29^1^*homozygotes and *Vps29^1^ / Df*) and appropriate controls. Our results indeed suggest the presence of a potential modifier, leading to a more severe climbing phenotype in *Vps29^1^* homozygotes; however, our rescue data confirms the specificity of the climbing phenotype for loss of *Vps29*.
